

Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial

Weller, Amber; Gleeson, John; Alvarez-Jimenez, Mario; McGorry, Patrick; Nelson, Barnaby; Allott, Kelly; Bendall, Sarah; Bartholomeusz, Cali; Koval, Peter; Harrigan, Susy; O'Donoghue, Brian; Fornito, Alex; Pantelis, Christos; Paul Amminger, G; Ratheesh, Aswin; Polari, Andrea; Wood, Stephen J; van der El, Kristi; Ellinghaus, Carli; Gates, Jesse

DOI:

[10.1111/eip.12769](https://doi.org/10.1111/eip.12769)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Weller, A, Gleeson, J, Alvarez-Jimenez, M, McGorry, P, Nelson, B, Allott, K, Bendall, S, Bartholomeusz, C, Koval, P, Harrigan, S, O'Donoghue, B, Fornito, A, Pantelis, C, Paul Amminger, G, Ratheesh, A, Polari, A, Wood, SJ, van der El, K, Ellinghaus, C, Gates, J, O'Connell, J, Mueller, M, Wunderink, L & Killackey, E 2018, 'Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: study protocol', *Early Intervention in Psychiatry*. <https://doi.org/10.1111/eip.12769>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is the peer reviewed version of the following article: Weller A, Gleeson J, Alvarez-Jimenez M, et al. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol. *Early Intervention in Psychiatry*. 2018;1–12. <https://doi.org/10.1111/eip.12769>, which has been published in final form at [10.1111/eip.12769](https://doi.org/10.1111/eip.12769). This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 17. Apr. 2024



Can anti-psychotic dose reduction lead to better functional recovery in first episode psychosis? A randomised controlled trial of antipsychotic dose reduction. The Reduce Trial: Study Protocol

Journal:	<i>Early Intervention in Psychiatry</i>
Manuscript ID	EIP-2018-089.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	04-Oct-2018
Complete List of Authors:	<p>Weller, Amber; Orygen, The National Centre for Excellence in Youth Mental Health; The University of Melbourne, Centre for Youth Mental Health Gleeson, John; Australian Catholic University, School of Psychology Alvarez-Jimenez, Mario; Orygen, The National Centre of Excellence in Youth Mental Health; The University of Melbourne, Centre for Youth Mental Health McGorry, Patrick; ORYGEN Research Centre, ; Nelson, Barnaby; University of Melbourne, Orygen, The National Centre of Excellence in Youth Mental Health Allott, Kelly; Orygen Youth Health Research Centre, The University of Melbourne, Centre for Youth Mental Health Bendall, Sarah; University of Melbourne, Orygen Research Centre Bartholomeusz, Cali; Orygen, the National Centre of Excellence in Youth Mental Health; University of Melbourne, Centre for Youth Mental Health Koval, Peter; The University of Melbourne, School of Psychological Sciences Harrigan, Susy; The University of Melbourne, Centre for Mental Health, School of Global and Population Health O'Donoghue , Brian; Orygen Youth Health; Orygen, The National Centre for Excellence in Youth Mental Health; The University of Melbourne, Centre for Youth Mental Health Fornito, Alex; Monash University Pantelis, Christos; Melbourne Neuropsychiatry Centre, Amminger, G Paul; ORYGEN Research Centre , ; Medical University of Vienna, Ratheesh, Aswin Polari, Andrea; Orygen Youth Health, Wood, Stephen; University of Birmingham, Psychology; Orygen, The National Centre for Excellence in Youth Mental Health; The University of Melbourne, Centre for Youth Mental Health van der El, Kristi; Orygen, The National Centre for Excellence in Youth Mental Health; The University of Melbourne, Centre for Youth Mental Health Ellinghaus, Carli; Orygen, The National Centre for Excellence in Youth Mental Health; The University of Melbourne, Centre for Youth Mental Health Gates, Jesse; Orygen Youth Health; Orygen, The National Centre for Excellence in Youth Mental Health O'Connell, Jessica; Orygen Youth Health</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Mueller, Marianne; Orygen, The National Centre for Excellence in Youth Mental Health; The University of Melbourne, Centre for Youth Mental Health Wunderink, Lex; Friesland Mental Health Services, Education and Research; UCP-UMCG, RGOc Killackey, Eoin; Orygen, The National Centre for Excellence in Youth Mental Health; The University of Melbourne, Centre for Youth Mental Health
Keywords:	First episode psychosis, Functional Recovery, Dose Reduction, Protocol, Antipsychotic Medication

SCHOLARONE™
Manuscripts

For Peer Review

1
2 Dose reduction in FEP: Study Protocol
3
4
5

6 Can anti-psychotic dose reduction lead to better functional recovery in first episode
7 psychosis? A randomised controlled trial of ~~antipsychotic~~~~anti-psychotic~~ dose reduction. The
8

9 Reduce Trial: Study Protocol
10
11
12

13 Amber Weller^{1,2}, John Gleeson⁵, Mario Alvarez-Jimenez^{1,2}, Patrick
14 McGorry^{1,2}, Barnaby Nelson^{1,2}, Kelly Allott^{1,2}, Sarah
15 Bendall^{1,2}, Cali Bartholomeusz^{1,2}, Peter Koval⁷, Susy Harrigan⁶,
16 Brian O'Donoghue^{1,2,4}, Alex Fornito⁸, Christos Pantelis^{9,10}, G. Paul Amminger^{1,2},
17 Aswin Ratheesh^{1,2,4}, Andrea Polari^{1,2,4}, Stephen J Wood^{1,2,3}, Kristi van der
18 EL^{1,2,4}, Carli Ellinghaus^{1,2,4}, Jesse Gates⁴, Jessica O'Connell⁴, Marianne Mueller^{1,2}, Lex
19 Wunderink¹¹, Eoin Killackey^{1,2}.

20
21
22
23
24
25
26
27 Correspondence: Eoin Killackey eoin.killackey@orygen.org.au
28

29 ¹Orygen, the National Centre of Excellence in Youth Mental Health
30

31 ²Centre for Youth Mental Health, The University of Melbourne
32

33 ³School of Psychology, University of Birmingham, Edgbaston UK
34

35 ⁴Melbourne Health
36

37 ⁵Australian Catholic University
38

39 ⁶Centre for Mental Health, School of Population and Global Health, University of Melbourne
40

41 ⁷School of Psychological Sciences, University of Melbourne
42

43 ⁸Monash Clinical and Imaging Neuroscience, School of Psychological Sciences, Monash
44 University
45

46 ⁹Melbourne Neuropsychiatry Centre
47


48 ¹⁰Department of Psychiatry, University of Melbourne
49

50 ¹¹Friesland Mental Health Services
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Dose reduction in FEP: Study Protocol

For Peer Review



Dose reduction in FEP: Study Protocol

Abstract

Aim: Anti-psychotic medication has been the mainstay of treatment for psychotic illnesses for over 60 years. This has been associated with improvements in positive symptoms and a reduction in relapse rates. However, there has been little improvement in functional outcomes for people with psychosis. At the same time there is increasing evidence that medications contribute to life shortening metabolic and cardio-vascular illnesses. There is also uncertainty as to the role played by anti-psychotic medication in brain volume changes.

Aim: The primary aim of the study is to compare functional outcomes at 24-months between an anti-psychotic dose reduction strategy with evidence based intensive recovery treatment (EBIRT) (DRS+) and an antipsychotic maintenance treatment with EBIRT (AMTx+).

Methods: A single-blind randomized controlled trial will test the whether ~~a dose reduction strategy in combination with our evidence based intensive recovery treatment (DRS+),+~~ leads to better vocational and social recovery than ~~continuous antipsychotic maintenance treatment in combination with evidence based intensive recovery treatment (AMTx+),+~~ over a 2-year period in 180 remitted first episode psychosis (FEP) patients. Additionally, we will examine the effect of DRS_± vs AMTx_± on physical health, brain volume and cognitive functioning. ~~In terms of safety this~~ This study will **also** determine whether those receiving DRS+ will be no worse off in terms of psychotic relapses over 2 years follow up.

Results: This paper presents the protocol, rationale and hypotheses for this study which commenced recruitment in July 2017.

Conclusion: This study will test whether an ~~alternative antipsychotic dose-reduction~~ recovery treatment leads to improved functioning and safer outcomes in FEP patients. It will also be the first controlled experiment of the effect of exposure to antipsychotic maintenance treatment on brain volume changes in this population.

Key words:

First-episode psychosis

Functional recovery

Dose reduction

Anti-psychotic medication

Protocol

Dose reduction in FEP: Study Protocol

Introduction

It is over 65 years since antipsychotic medications were introduced and became the mainstay of treatment for psychotic illnesses. ~~There has undoubtedly been many benefits of their use in the control of symptoms, particularly positive symptoms of psychotic illness, and the reduction of relapse rates (Addington, Killackey, & Marulanda, In Press). Despite this, and even with the introduction of second generation antipsychotic medication there has been little indication that people with psychotic illness have returned to functional roles in any great number. For example, people diagnosed with psychotic (Eóin Killackey & Allott, 2013) illnesses are less likely to complete their secondary education (Waghorn et al., 2012) and unemployment remains a highly prevalent problem associated with the disorder. Loneliness is also a significant issue for young people with psychosis, so much so that the onset of psychosis has been characterised as a social network crisis which is not ameliorated by current interventions (Horan, 2006). In a range of other functional domains, housing security, (Harvey, Killackey, Groves, & Herrman, 2012) physical health (V. Morgan et al., 2013), and social relationships and engagement in community (V. A. Morgan et al., 2011), people with psychotic illnesses have worse outcomes than the general population. Antipsychotic medications are effective at addressing the symptoms of illness, but have little to no success at addressing many of the associated problems of the illness~~ There has undoubtedly been many benefits of their use in the control of symptoms, particularly positive symptoms of psychotic illness, and the reduction of relapse rates¹. Despite this, and even with the introduction of second-generation antipsychotic medication there has been little indication that people with psychotic illness have returned to functional roles in any great number. For example, people diagnosed with psychotic illnesses² are less likely to complete their secondary education³ and unemployment remains a highly prevalent problem associated with the disorder. Loneliness is also a significant issue for young people with psychosis, so much so that the onset of psychosis has been characterised as a social network crisis which is not ameliorated by current interventions⁴. In a range of other functional domains, housing security,⁵ physical health⁶, social relationships and engagement in community⁷, people with psychotic illnesses have worse outcomes than the general population. Antipsychotic medications are effective at addressing the symptoms of illness but have little to no success at addressing many of the associated problems of the illness (Alvarez-Jimenez et al., 2016)⁸. Yet, it is these problems that people living with psychosis most want ~~most~~ addressed (Ramsay et al., 2011)⁹.

Data from ~~studies~~ papers published over the last 511 years (Wunderink, Nieboer, Wiersma, Sytema, & Nienhuis, 2013; Wunderink et al., 2007)^{10,11} have raised the question of how the best balance or

Dose reduction in FEP: Study Protocol

“sweet-spot” is struck between exposure to antipsychotic medication, symptomatic improvement, the minimisation of iatrogenic harm and maximising functional recovery (Correll, Rubio, & Kane, 2018).¹² The study described in this paper seeks to answer this question.

Background

~~After remission from acute symptoms of psychosis is achieved, most treatments for psychosis have focussed upon the prevention of psychotic relapse (N. Andreasen et al., 2005; Program, 2016). Relapse prevention is a worthy clinical goal, due to the potential for distress and other risks associated with acute symptoms, the direct cost of multiple hospital visits associated with relapse (Knapp et al., 2013), as well as relapsing courses of psychosis being up to 4 times more expensive than non-relapsing courses (Almond, Knapp, Francois, Toumi, & Brugha, 2004; Ascher-Svanum et al., 2010). Less focus has been placed on improving social and vocational functioning despite these being the primary goals of people who experience psychosis~~ After remission from acute symptoms of psychosis is achieved, most treatments for psychosis have focussed upon the prevention of psychotic relapse^{13,14}. Relapse prevention is a worthy clinical goal, due to the potential for distress and other risks associated with acute symptoms, the direct cost of multiple hospital visits associated with relapse¹⁵, as well as relapsing courses of psychosis being up to 4 times more expensive than non-relapsing courses^{16,17}. Less focus has been placed on improving social and vocational functioning despite these being the primary goals of people who experience psychosis (Iyer, Mangala, Anitha, Thara, & Malla, 2011; Ramsay et al., 2014)¹⁸. For this reason, as well as being the cause of 50% of the total illness costs, functional recovery of people with psychotic illness warrants further attention (Alvarez Jimenez et al., 2016). In this context we define functional recovery to mean- age appropriate vocational functioning, having social outlets, such as friends beyond oneself's immediate family and participation in oneself's community through such activities as voting.

The impact of antipsychotic maintenance treatment

~~Current evidence based treatment guidelines recommend antipsychotic maintenance treatment for 2-5 years after a First Episode of Psychosis (FEP) (Program, 2016), followed by annual review (Program, 2016). In reality, maintenance treatment can continue for decades (N. C. Andreasen, Liu, Ziebell, Vera, & Ho, 2013), partly due to the lack of clarity and evidence around how long individuals should receive antipsychotic treatment (Program, 2016; Sohler et al., 2016). The goal of current guidelines is to prevent symptomatic relapse rates in FEP clients~~ Current evidence based treatment guidelines recommend antipsychotic maintenance treatment for 2-5 years after a First Episode of Psychosis (FEP)¹³, followed by annual review¹³. In reality, maintenance treatment can continue for decades¹⁹, partly due to the lack of clarity and evidence around how long individuals should receive

Dose reduction in FEP: Study Protocol

antipsychotic treatment^{13,20}. The goal of current guidelines is to prevent symptomatic relapse rates in FEP clients^{(Chen et al., 2010; Emsley, Chiliza, & Asmal, 2013)21,22}. Arguments in favour of ongoing maintenance treatment are that: in the absence of medication, risk of relapse rises significantly, episodes of relapse tend to become longer after the initial episode(Emsley, Chiliza, & Asmal, 2013)²²; response to medication takes longer; and approximately 14% at each relapse will not respond to medication(Emsley, Chiliza, Asmal, & Harvey, 2013). While maintenance treatment is generally successful at treating positive psychotic symptoms(Sohler et al., 2016), the associated side-effects of antipsychotic medication can be a case of significant harm. These side-effects include weight gain (Grundy, Brewer, Cleeman, Smith, & Lenfant, 2004; Klemm et al., 2011), sexual dysfunction(Program, 2016) and possible contribution to poor functional recovery in^(Wunderink et al., 2013) people with positive symptom remission. These associated side-effects can result in poor medication adherence(Coldham, Addington, & Addington, 2002). In fact adherence to antipsychotic medication is poor in FEP; around 60% of them have either non adherence or poor adherence. Further implications of maintenance treatment include metabolic disturbances which lead to increased risks for cardiovascular disease and diabetes^(De Hert et al., 2011). One consequence of this is the 20-30 year reduction in life expectancy in people with psychosis^(Olsson, Gerhard, Huang, Crystal, & Stroup, 2015; Subotnik, Nuechterlein, Ventura, & Marder, 2011). Metabolic and cardiovascular illness, in large part due to antipsychotic medication^(De Hert et al., 2011), accounts for the majority of this mortality. (Hage et al., 2018)

; response to medication takes longer; and approximately 14% at each relapse will not respond to medication²³. While maintenance treatment is generally successful at treating positive psychotic symptoms²⁰, the associated side-effects of antipsychotic medication can be a case of significant harm. These side-effects include weight gain^{24,25}, sexual dysfunction¹³ and possible contribution to poor functional recovery in¹⁰ people with positive symptom remission. These associated side-effects can result in poor medication adherence²⁶. Adherence to antipsychotic medication is poor in FEP; around 60% of them have either non adherence or poor adherence²⁷. Further implications of maintenance treatment include metabolic disturbances which lead to increased risks for cardiovascular disease and diabetes and the potential for a 20-30 year reduction in life expectancy in people with psychosis^{28,29,30}. Metabolic and cardiovascular illness, in large part due to antipsychotic medication²⁸, accounts for the majority of this mortality.³¹

In addition, maintenance treatment studies(Waghorn et al., 2012)³ and meta-analyses(Alvarez-Jimenez, Parker, Hetrick, McGorry, & Gleeson, 2011)³² over the last 10 years have found a relationship between exposure to antipsychotic medication and changes in brain volume. Recent

Dose reduction in FEP: Study Protocol

cross-sectional evidence indicates that antipsychotic medications may produce reductions in grey and white matter volumes (Alvarez Jimenez et al., 2011)³² (Bola & Mosher, 2002).³³ One study in particular found medicated FEP patients to display significant cortical thinning in the dorsolateral prefrontal and temporal cortices when compared to unmedicated FEP patients, who had cortical thickness measures similar to controls (Lesh et al., 2015).³⁴ Moreover, a 7-year longitudinal neuroimaging study in FEP showed that loss of brain tissue occurs at the rate of 0.56cc56 cubic centimetres in patients receiving an average of 4mg/day of haloperidol (dose equivalent) over a 1-year period (N. C. Andreasen et al., 2013).¹⁹ Intensity in dose years of antipsychotic treatment was associated with reductions in total cerebral volume as well as frontal lobe and white matter volumes. However, without a control group this study could not establish whether brain volume reductions are a direct consequence of maintenance treatment or rather are accounted for by other illness-related factors. Given that early psychosis is associated with significant loss of grey matter volume over time relative to healthy controls (Bowie, McLaughlin, Carrion, Auther, & Cornblatt, 2012)³⁵, there is a possibility that medication discontinuation could reduce this loss, or preserve brain changes such that they are comparable to neurotypical same-age peers. Further, some evidence suggests that antipsychotic treatment may alter cerebral function in FEP (Lesh et al., 2015; Lui et al., 2010) (Radua et al., 2012; Sarpal et al., 2015) and the impact of a dose reduction strategy on functional connectivity of resting-state neural networks is currently unknown.^{34,36-38} Additionally, cognitive function may be adversely affected by maintenance treatment. Evidence for this comes from three Three naturalistic studies in prodromal and established schizophrenia groups showingshow a relationship between level of exposure to antipsychotic medication and decline in cognitive function over time (Faber, Smid, Van Gool, Wiersma, & Van Den Bosch, 2012; Husa et al., 2014; Weickert et al., 2013)³⁹⁻⁴¹. As symptom intensity or persistence may confound this relationship. Furthermore, meta-analytic evidence suggests that the processing speed impairment observed in psychotic disorders is significantly associated with chlorpromazine equivalent daily dose.⁴² As symptom intensity or persistence may confound the relationship between cognitive performance and antipsychotic dose, randomised controlled trials are required. A recent small (N=53) guided anti-psychotic discontinuation RCT in FEP found that cognitive function improved in remitted FEP clients who received guided discontinuation compared with those who received maintenance treatment over a five month follow up period (Faber et al., 2012). These differences may be explained by the fact that antipsychotic dopamine blockade can lead to impaired verbal learning in psychosis (Weickert et al., 2013). If the positive impact of maintenance/reduced antipsychotic treatment combined with psychosocial treatment on the brain's structure can be

Dose reduction in FEP: Study Protocol

confirmed, we will investigate whether attenuation of brain volume reductions acts as a mediator/moderator of psychosocial functioning.^(Bola & Mosher, 2002; Patrick McGorry, 2005)

This is in line with previous research that has also shown that adherence to high/standard-dose maintenance treatment is associated with poorer psychosocial functioning early in the course of recovery, suggesting that a strong focus on high-dose maintenance medication may interfere with long-term recovery.^(Wunderink et al., 2013) This is also consistent with the follow-up results from the Episode II trial (J. F. Gleeson et al., 2009).

Although maintenance treatments for psychotic illnesses significantly reduce relapse rates compared with placebo, they do not achieve the functional goals of people who experience psychosis.

Two small double-blind placebo-controlled crossover studies of inpatients with schizophrenia (N=27 and N=19, respectively) found that antipsychotic medication was associated improved cognitive performance compared with placebo^{43,44}. A recent guided anti-psychotic discontinuation RCT in FEP (N=53) found that cognitive function improved in remitted FEP clients who received guided discontinuation compared with those who received maintenance treatment over a five month follow up period⁴⁰. Previous research has also shown that adherence to high/standard-dose maintenance treatment is associated with poorer psychosocial functioning early in the course of recovery, suggesting that a strong focus on high-dose maintenance medication may interfere with long-term recovery¹⁰. This is also consistent with the follow-up results from the Episode II trial⁴⁵. A recent critical review also proposed that although anti-psychotic maintenance may be efficacious in mid-term treatment of psychosis, there is a paucity of evidence supporting the efficacy of this treatment approach in the long-term, this supports further investigation of a dose reduction strategy¹².

Is dose reduction the answer?

The negative impacts of long-term maintenance have raised the question of whether dose reduction might be associated with better outcomes for individuals affected by psychotic disorders. Recent evidence showing that functioning improves with a strategy to reduce the dose of antipsychotic medication suggests that functional recovery may be suppressed by long-term exposure to antipsychotic medication^(P. D. McGorry, Alvarez Jimenez, & Killackey, 2013; Wunderink et al., 2013)^{10,46}. A meta-analysis of RCTs of antipsychotic treatments in FEP clients showed that approximately 40% of placebo-treated FEP clients had not relapsed at 1-year follow up^(Alvarez Jimenez et al., 2011)³². Subsequently, one recent RCT revealed that, when compared with continuous maintenance treatment, the discontinuation of maintenance treatment in FEP led to improved recovery at 7 years follow up^(Wunderink et al., 2013)¹⁰. Importantly, this occurred in the absence of intensive psychosocial treatments that may

Dose reduction in FEP: Study Protocol

hasten improvement of functioning and prevent relapse^{(Alvarez-Jimenez et al., 2011) 32}. Thus, recovery may be enhanced or hastened if a dose reduction strategy were combined with intensive evidence based psychosocial interventions. These findings suggest that, despite current guidelines, FEP clients may not require maintenance treatment for the initial recommended two-year minimum period to attain recovery and prevent relapse. Indeed, previous research has shown that it is early functional recovery rather than symptomatic recovery that predicts functional recovery at 7.5 years^{(Alvarez-Jimenez et al., 2012) 47}.

Arguably, patient non-adherence^{(Gitlin et al., 2001) 48} and planned discontinuation of maintenance treatment both pose risks for relapse after FEP^{(Alvarez-Jimenez et al., 2012) 47}. However, as reduction in symptoms ~~dedoes~~ not automatically translate into functional gains. Prioritising relapse prevention without also giving full consideration to the implications for functional recovery may compromise the long-term outcomes most valued by those who experience the illness^{(PD-McGorry, 2007; Ramsay et al., 2011) 9,49}.

Management of relapse risk therefore, should be balanced with a focus on functional recovery and the costs of long-term continuous maintenance treatment, including probable enhancement in functioning^{(Alvarez-Jimenez et al., 2011) 32}. A promising balanced approach to treatment includes a dose reduction strategy, combined with intensive and recovery-focussed psychosocial treatments with vigilant monitoring for early signs of relapse^{(Carpenter, Appelbaum, & Levine, 2003) 50}.

Supplementary to a dose reduction strategy, the use of an evidence-based intensive recovery treatment (EBIRT) should be employed to improve likelihood of overall functional outcomes. In the present study, EBIRT combines two previously trialled interventions. These interventions are Individual Placement and Support (IPS) for vocational recovery and CBT for Relapse Prevention. IPS in addition to specialist FEP treatment has produced significantly better outcomes in gaining employment, hours worked, jobs acquired, and longevity of jobs compared to specialist FEP treatment alone^{(J. F. Gleeson et al., 2009; E. Killackey, Jackson, & McGorry, 2008) 45,51}. CBT for relapse prevention combined with specialist FEP treatment when compared with specialist FEP treatment alone^{(J. F. Gleeson et al., 2009) 45} led to a significant reduction in relapse rates at 7-months follow up in FEP clients who met remission on positive symptoms. This effect was sustained at 1 year, and relapse rates were kept to historically low levels beyond this time point (30% at 2.5 years)^{(J. F. Gleeson et al., 2009; J. F. M. Gleeson et al., 2013) 45,52}. However, these differences were no longer significant at 30-month follow-up.

~~Importantly, 83% of clinicians providing care to people experiencing~~ (Thompson, Singh, & Birchwood, 2016)~~Importantly, 83% of clinicians providing care to people experiencing~~ FEP would

1
2 Dose reduction in FEP: Study Protocol
3
4
5

6 support a carefully monitored dose reduction strategy after patient relapse, and believe this would
7 improve the quality of life of their clients⁵³. This further supports the acceptability of a dose
8 reduction strategy, particularly in a FEP setting⁴⁸, (~~National Collaborating Centre for Mental Health,~~
9 ~~2014; ORYGEN Youth Health, 2010)~~^{54,55}
10
11
12
13

14 Aims

15 The primary aim of the study is to compare functional outcomes between a dose reduction strategy
16 with EBIRT group (DRS+) and an antipsychotic maintenance treatment with EBIRT group (AMTx+) at
17 24-months follow up.
18
19

20 This study has a range of secondary aims:

- 21 1. To compare physical health and metabolic profiles between DRS+ and AMTx+ at 24-months
22 follow up.
- 23 2. To compare grey and white matter volume between DRS+ and AMTx+ at 24-months follow
24 up.
- 25 3. To compare brain activity during resting-state between DRS+ and AMTx+ at 24 months
26 follow up^{—*}.
- 27 4. To compare cognitive functioning between DRS+ and AMTx+ at 24-months follow up.
- 28 5. To compare remission and relapse rates between DRS+ and AMTx+ at 24-months follow up.
29
30
31
32
33

34
35
36 *This is a largely exploratory aim, however based on the limited literature in this area we hypothesise
37 that the DRS+ group would display greater resting state functional connectivity than the AMTx+ and
38 healthy control groups
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

1
2 Dose reduction in FEP: Study Protocol
3
4
5

6 Primary hypothesis

8 H1: Remitted FEP patients randomised to DRS+ will achieve superior social and vocational
9 functioning at 24-months follow up, compared with remitted FEP patients randomised to AMTx+.

11 Secondary hypotheses

12 H2: Participants randomised to DRS+ will have less reduction in grey and white matter volume than
13 participants randomised to AMTx+ at 24-months follow up.

14 H3: Degree of antipsychotic exposure will be negatively associated with grey and white matter
15 volume at 24-months follow up. Further, it is expected that change in neural activity during resting
16 state will differ significantly between the DRS+ and AMTx+ groups at 24-months follow-up.

17 H4: Participants randomised to DRS+ will have better cognitive functioning compared to participants
18 randomised to AMTx+ at 24-months follow up.

19 H5: Participants in the AMTx group will have experienced fewer relapses at 24-months follow up.

20 H6: Participants randomised to DRS+ will have significantly better metabolic indices (defined as
21 being within normal parameters) and an improved physical health status at 24-months follow up.
22
23
24
25
26
27
28

29 Ethical approval

30 This study was approved by the Melbourne Health Human Research Ethics Committee
31 (HREC/16/MH/309) in February 2017 and began recruiting participants in July 2017. The trial is
32 registered on the Australian and New Zealand Clinical Trials Registry (12617000870358).
33
34

Formatted: Font: 12 pt

36 Methodology

37 Study Design

38 This study is a single blinded non-placebo randomised controlled trial where research assistants are
39 blinded to treatment allocation.
40
41
42

43 Study Setting

44 This study will be conducted at the Early Psychosis Prevention and Intervention Centre (EPPIC), a
45 sub-program of Orygen Youth Health (OYH). OYH is a youth public mental health service in
46 Melbourne for 15 to 25-year-olds (inclusive). EPPIC is a comprehensive specialist early psychosis
47 program that provides outpatient case management ~~and psychiatric treatment, psychosocial~~
48 intervention and psychiatric treatment. OYH is co-located with Orygen, the National Centre of
49 Excellence in Youth Mental Health and the Centre for Youth Mental Health, The University of
50
51
52
53
54
55
56
57
58
59
60

1
2 Dose reduction in FEP: Study Protocol
3
4
5

6 Melbourne. EPPIC provides up to 2 years of specialised care after which clients are transferred to
7 another service depending upon the level of care required. A proportion of clients receive follow-up
8 care within primary care settings, while others may continue to require case-management and
9 specialist care and are therefore transferred to the adult mental health service. The Reduce Trial will
10 embed specific resources within EPPIC, including a proportion of one psychiatry registrar position, a
11 Vocational Support Worker and a number of specialist Reduce trial case managers, who will provide
12 the medical oversight, the vocational recovery support and the clinical case management for trial
13 participants, respectively.
14
15
16
17

18 Inclusion and Exclusion Criteria

19 Inclusion and Exclusion Criteria have been designed to reflect 'real-world' characteristics of young
20 people presenting to clinical settings with a FEP.
21
22

23 Inclusion Criteria: (i) Current client of EPPIC; (ii) A confirmed diagnosis of first episode of a DSM
24 5 (Association, 2013)⁵⁶ psychotic disorder or mood disorder with psychotic features (Association,
25 2013; First MB, 2015);^{56,57}; (iii) Aged 15-25 years (inclusive); (iv) ≥ 3 months of remission on positive
26 symptoms of psychosis in the first year of antipsychotic treatment (participants must currently be
27 taking their prescribed anti-psychotic medication) at EPPIC (a score of ≤ 3 (mild) on the
28 hallucinations, unusual thought disorder, conceptual disorganisation, and suspiciousness subscale
29 items of the Brief Psychiatric Rating Scale (BPRS) (Ventura et al., 1993)⁵⁸ for the past two weeks and a
30 score ≤ 3 on the hallucinations, unusual thought content, conceptual disorganisation, and
31 suspiciousness subscales of the BRPS (Ventura et al., 1993)⁵⁸ for the past 3 months based on a
32 systematic clinical file review and collateral information collected from the participant's treating
33 team in EPPIC (as needed); (v) Low suicidality defined as a score of 4 or below on the BPRS (Ventura
34 et al., 1993)⁵⁸ sustained for the past 1-month period prior to baseline; (vi) The young person is
35 willing for a caregiver to be informed about the study and will have at least weekly contact with their
36 caregiver; (vii) Ability to provide written informed consent.
37
38
39
40
41
42

43 Exclusion Criteria: (i) A documented history of an intellectual disability or IQ < 70 ; (ii) Inability to
44 converse in or read English; (iii) Women who are currently pregnant or breastfeeding; (iv)
45 Neurological disorder: (illness of the brain, nerves or spinal cord which could not better explain the
46 presence of psychosis).
47
48

49 Recruitment, Consent, and Enrolment and Randomisation

50 Participants will be recruited into the trial through a number of strategies- including regular case
51 review discussions between the Reduce research assistant (RA) and EPPIC Consultants, direct
52
53
54
55
56
57
58
59
60

Dose reduction in FEP: Study Protocol

referral to Reduce from EPPIC Clinicians and through the RA attending regular EPPIC team meetings to discuss ongoing eligibility of clients nearing three months of psychotic remission. Potential participants are then approached to take part in the trial by either the RA, Reduce registrar or case manager. They are given ample time to consider the option to take part in Reduce and are encouraged to discuss this with their family, local doctor and other supports. Before being enrolled in the study all participants will provide written and informed consent. In the case of minors, their parent or legal guardian will also be required to provide written and informed consent. After the consent process is complete, a Core Baseline assessment is administered by the research assistant. Eligibility is assessed, using the BPRS (Ventura et al., 1993)⁵⁸ and the SCID-RV (First MB, 2015).

~~Participant clinical notes will also be used for collateral information to confirm eligibility. If eligibility is confirmed from the above assessments, participants will be randomised to either AMTx+ or DRS+ at a ratio of 1:1 and randomisation will be stratified by sex assigned⁵⁷. Participant medical files and EPPIC clinical files will also be used for collateral information to confirm eligibility~~

Method of Assigning participants to Treatment Groups and Randomisation

An independent statistician will organise the randomisation. The randomisation will be stratified by sex at birth (male vs. female) and baseline diagnosis (affective vs. non-affective) as these

characteristics are associated with key outcomes in this study and any chance imbalances may bias the analysis. ~~Following randomisation, the Non-Core Baseline Assessment will be completed within 3~~

~~weeks. Participants will be allocated to either the EBIRT (AMTx+) or EBIRT (DRS) treatment groups using randomly permuted blocks of varying size within each stratum, to maintain approximately equal group sizes over time. The randomisation sequences will be concealed within a secured password protected website. On obtaining informed consent of a new participant, the delegated research team member will access this website and enter the participant's details. The delegated research team member will then inform the treating team the randomisation outcomes who will then inform and discuss this with the participant.~~

A client identification (ID) number will be allocated to clients approached to ascertain their eligibility to participate in the study. Each eligible participant will be allocated to a unique and sequential randomization number.

Healthy Control Group

Because the age range of participants covers a time of significant neurodevelopment, 40 healthy controls aged 15-25 years (inclusive), living in the EPPIC catchment, with no history of mental illness, neurological condition or antipsychotic medication treatment will also be recruited. They will undergo MRI scanning, be cognitively assessed and have physical health indicators measured (except

Formatted: Font color: Black, English (U.K.)

Formatted: Font: Not Italic, Font color: Black, English (U.K.)

Formatted: Font color: Black, English (U.K.)

Dose reduction in FEP: Study Protocol

bloods) at the same four time points as the DRS+ and AMTx+ groups (baseline, 9-months, 15-months and 24-months). This will provide objective control data to determine whether there are physical health, brain volume and neural activation or cognition changes and if they are related to illness, medication or typical development.

Outcome Measures

The primary outcome measure is the Social and Occupational Functioning Scale (Goldman, Skodol, & Lave, 1992) (SOFAS) at 24 months.⁵⁹ (SOFAS) at 24 months. In addition to the primary outcome measure, a number of measures will assess physical health and metabolic profiles, brain volumes/activity, cognitive functioning and remission and relapse rates at 24-months.

Secondary Endpoint measures

Symptomatology

Remission and relapse of positive symptoms will be assessed using the expanded Brief Psychiatric Rating Scale (Overall & Gorham, 1962) (BPRS) in treatment groups only. Remission of negative symptoms will be assessed using the Scale for Assessment of Negative Symptoms (SANS) (N.C. Andreasen, 1984).

Neurocognitive assessments

A battery of neurocognitive tests including the Brief Assessment of Cognition in Schizophrenia (Keefe et al., 2008) Remission and relapse of positive symptoms will be assessed using the expanded Brief Psychiatric Rating Scale⁶⁰ (BPRS) in treatment groups only. Remission of negative symptoms will be assessed using the Scale for Assessment of Negative Symptoms (SANS)⁶¹. The a priori clinically significant degree of difference on duration of relapse is 7 days, in accordance with published duration criteria⁵².

Neurocognitive assessments

A battery of neurocognitive tests including the Brief Assessment of Cognition in Schizophrenia⁶² (BACS App) will be used to assess cognitive functioning in all groups, including healthy controls. Further detail of the full neurocognitive battery can be found in the Schedule of Assessments (Table 1).

INSERT TABLE 1 ABOUT HERE

1
2 Dose reduction in FEP: Study Protocol
3
4
5

6 Physical health assessments

7
8 Blood pressure, weight, height and waist circumference will also be recorded in all groups including
9 healthy controls.
10

11 Haematological investigations

12
13 Physical health will be measured by clinical blood analysis evaluating fasting glucose, haemoglobin
14 A_{1c}, triglycerides and ~~lipid levels~~ Total HL cholesterol in the treatment groups only.
15

16 Brain imaging

17
18 Brain volume will be quantified in both treatment groups and healthy controls by high-resolution
19 magnetic resonance imaging (MRI). In addition to structural MRI, functional resting state data will
20 also be collected.
21

22 Study Intervention

23 Intervention

24
25 After randomisation and allocation to one of the two conditions, all participants will commence the
26 intensive EBIRT phase in which they will attend up to twice weekly individual therapy and vocational
27 support sessions until Month 9.
28

29 Evidence-Based Intensive Recovery Treatment (EBIRT)

30
31 EBIRT combines two well-validated and manualised psychosocial interventions: Individual Placement
32 and Support (IPS) for vocational recovery and Cognitive Behaviour Therapy (CBT) for Relapse
33 Prevention. EBIRT will be delivered in two phases; a 9-month intensive phase which entails up to two
34 sessions of individual therapy (one CBT sessions and one IPS session) per week for 9-months. All
35 participants will receive 9 months of the EBIRT intensive phase. This will followed by a 6-9 month
36 (dependent on tenure remaining in service)- maintenance/monitoring phase in which individual
37 therapy sessions will be delivered every 4-6 weeks.
38
39
40

41
42 The first component of EBIRT is CBT. This will be provided by a therapist trained in CBT and is
43 comprised of six or more modules of therapy delivered over the 9-month intensive period. The six
44 phases of EBIRT intervention include: (1) initiation of vocational intervention (2) formulation and
45 agenda setting; including vocational goal setting; (3) engagement and assessment for recovery and
46 risk for relapse; (4) psychoeducation with a focus on relapse; (5) early warning signs and relapse
47 planning – will also involve family members with participant's consent; and, treatment and progress
48 review (6). Additional optional modules may be drawn upon depending on case formulation and
49 clinical determination in collaboration with the participant include: substance abuse, stress
50
51
52
53
54
55
56
57
58
59
60

Dose reduction in FEP: Study Protocol

management, and co-morbid anxiety and depression at the investigator's participant or clinician discretion. The second component of EBIRT is IPS. This will focus on (a) focussed upon competitive employment, education or training as an outcome; and (b) focussed upon immediate job/education searching and will be delivered by a Youth Specialist Vocational Consultant. In tandem with EBIRT, participants will be randomly assigned following baseline assessment to either the DRS+ or AMTx treatment conditions.

DRS will comprise a 9-month EBIRT phase (DRS+). The comparator group will receive AMTx and EBIRT (AMTx+). The EBIRT intervention will be the same in both groups. The AMTx group treatment, including medication prescription will be in accordance with published treatment guidelines. The Reduce trial clinicians will collect data on frequency, content and duration of therapy sessions in order to measure treatment compliance for the duration of the 15-18 month EBIRT treatment.

At Month 9, all participants will transition into the lower intensity monitoring phase of EBIRT in which they will attend individual therapy sessions with their Reduce case manager every 4-6 weeks for a minimum of 6 months. All participants will receive a minimum of at least 15 months of EBIRT therapy however they may receive up to total Reduce treatment and a maximum of 18 months, depending on the balance of how long their time left in psychotic symptoms take to stabilise upon entry into EPPIC. All This means that some participants will be entitled to receive a total of 24- months of EPPIC treatment whereby, some participants will receive 27 months total EPPIC treatment. Participants are entitled to the full EPPIC treatment package throughout this time and can have the frequency of appointments with EPPIC team increased should there be a clinical indication to do so. Differences in EPPIC treatment will be recorded.

Dose Reduction Strategy (DRS+) group

Participants who are randomised to this arm of the trial will be offered a gradual dose reduction of their antipsychotic medication at their next medical review after randomisation. Medication will be tapered under close medical supervision over 3-months after allocation to the DRS group to minimise the risk of relapse due to abrupt discontinuation. The rate of tapering will be a 25% dose reduction (or as near to 25% as the medication allows) of the pre-reduction dose every month for 3 months, if clinically safe as determined by the EPPIC treating team, until the participant reduces a dose that is considered clinically safe, whereby some participants will completely cease taking the antipsychotic medication. This will see some variation in participants' reduction schedule. All data on the rate of dose reduction will be collected by the Reduce clinicians to measure the variations in participant treatment.

Formatted: Font: 11 pt

1
2 Dose reduction in FEP: Study Protocol
3
4
5

6 Antipsychotic Maintenance Treatment (AMTx) group

7
8 Participants will be prescribed medication as clinically indicated, concordant with the Australian
9 Clinical Practice Guidelines for FEP ([National Collaborating Centre for Mental Health, 2014](#); [ORYGEN](#)
10 [Youth Health, 2010](#)),^{54,55}. These guidelines recommend the use of the lowest effective dose of
11 atypical antipsychotics.
12

13
14 All trial participants will have access to all components of treatment at EPPIC, including psychiatric
15 care, case management, psychosocial program, acute inpatient care and outreach as clinically
16 indicated. ([N.C. Andreasen, 1984](#); [Keefe et al., 2008](#); [Ventura et al., 1993](#))^{58,61,62}
17

18 Safety Measures

19
20 Participants will be managed within the EPPIC clinic at OYH. Participants will be monitored by the
21 treating team. Clinical appointments can be held more frequently when clinically indicated. In
22 addition, the BPRS ([Ventura et al., 1993](#))⁵⁸ and SOFAS ([Goldman et al., 1992](#))⁵⁹ scales will administered
23 weekly by the participant's EBIRT Clinician to assess for participant symptomatic relapse, and to
24 measure the acceptability and safety of the prescribed dose. The SOFAS will measure functioning
25 during the 9-month intensive phase. Safety ~~These safety~~ assessments will ~~then~~ continue to occur
26 every 4-6 weeks up until Month 24 and administered by either the EBIRT Clinician or the Research
27 Assistant.
28

29 Relapse and Temporary Pause or Complete Discontinuation from DRS+

30
31 In the event of symptomatic relapse or worsening of symptoms, and the participant meeting the
32 criteria for relapse described in Table 2, the participant's dose reduction treatment may be
33 temporarily paused.
34

35
36 Table 2 presents the criteria used to define psychotic relapse and will result in a temporary pause
37 from the DRS+ treatment. These relapse criteria have been developed with the aim of reflecting
38 'real-world' relapse of FEP. Participants must satisfy either Criteria 1, 2 or 3 in combination with 4 to
39 meet relapse criteria. ([Ventura et al., 1993](#))⁵⁸ There is also a 'fail-safe' option should stopping the DRS
40 be clinically indicated.
41

42
43 *TABLE 2 HERE*
44

45
46 If the above criteria are not met but the participant is considered by their treating clinical team to
47 have significantly deteriorated in relation to psychotic symptoms compared to baseline, and clinical
48 response is deemed necessary, they may also be temporarily paused from the DRS+. Participants will
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Dose reduction in FEP: Study Protocol
3
4
5

6 be monitored by their treating team and study personnel and regularly assessed for relapse,
7 psychotic exacerbations and functioning.
8

9
10 In the event of a temporary pause in the dose reduction strategy the clinical team will ~~make a~~
11 ~~decision as to decide~~ whether the participant should restart their antipsychotic medication or
12 increase their dose. Any changes made will be in consultation with the participant.
13

14 If antipsychotic medication is recommenced or if the dose is increased, it will be titrated up until an
15 effective dose is reached. Titration will occur at a pace appropriate to the individual's clinical
16 presentation and should allow adequate time for a response at each dosing interval. In this case,
17 psychiatry registrars will discuss appropriate dose with treating consultants and ensure any changes
18 are documented. If the participant fails to achieve satisfactory recovery defined by persistence of
19 severe psychotic symptoms whilst consistently meeting criteria described in Table 2 for 3 months
20 following the initial relapse, or if they become pregnant during the study they will be completely
21 discontinued from DRS+, whilst still remaining in EPPIC and receiving EBIRT. These participants will
22 also be invited to continue with the research assessments and included in intention-to-treat
23 analyses.
24
25
26
27
28

29 Table 3 outlines the study schema
30

31 *TABLE 3 HERE*
32

33 Participants discontinued from the AMTx+ group will continue to receive treatment in accordance
34 with the Australian Clinical Practice Guidelines ~~and may choose not to participate in EBIRT.~~ If they
35 wish they may continue with EBIRT and the research assessments. These participants will also be
36 included in intention-to-treat analyses.
37
38

39 Withdrawal Criteria

40 A participant will be withdrawn from the study if they choose to no longer participate in the Reduce
41 study voluntarily, ~~fail to achieve satisfactory recovery defined by persistence of severe psychotic~~
42 ~~symptoms whilst consistently meeting criteria described in Table 2 for 3 months following the initial~~
43 ~~relapse, or if they become pregnant during the study.~~ A participant will be considered 'withdrawn'
44 from the study in cases where all involvement in the trial is ceased, ~~and no further follow up is~~
45 enacted
46
47
48

49 Blinding

50 The delegated study statistician will be blind to treatment allocation. Research assistants (RAs) will
51 also be blind to treatment allocation. The study RAs will be kept blind to treatment allocation using
52
53
54
55
56
57
58
59
60

1
2 Dose reduction in FEP: Study Protocol
3
4
5

6 the following processes: (a) regular reminders will be sent to clinical staff at EPPIC, regarding the
7 importance of the blind; (b) at the start of each research interview the RA will remind the
8 participants of the importance of the blind; (c) the RA will have restricted access to participants'
9 medical records. The unblinded Project Manager will have access to the participant's medical
10 records and will retrieve and provide study RA's with any information that is required (i.e. for
11 screening). Because the extent and rate of dose tapering in each individual case requires clinical
12 tailoring in response to preceding dose reductions, it is not feasible to utilise a placebo control, so
13 medication treatment will be open-label, with medications chosen by EPPIC psychiatrists.
14
15
16
17

18 Statistical methods and determination of sample size

19 Data analysis will be conducted at the completion of the study (24-months from last patient first
20 visit) and as such there will be no interim analyses conducted. The primary outcome is SOFAS score
21 at two-year follow-up. Calculations of effect size are based on detecting a two-year follow-up effect
22 size of $d=0.505$, based on our previous relapse prevention studies which found a group difference of
23 this magnitude on the SOFAS at two-year follow-up. Power is set at 0.85, $\alpha = .05$ (two-tailed). The
24 estimated sample size is 144 ($n=72$ per group). To accommodate an attrition rate of 20%, the target
25 sample size will be 180, or 90 participants per treatment group. Differences on social and vocational
26 functioning measures will be examined using mixed model repeated measures and intention-to-treat
27 analysis, which are preferred methods for the analysis of clinical trial data in psychiatry. The a priori
28 clinically significant degree of difference on duration of relapse is 7 days, in accordance with
29 published duration criteria (J. F. M. Gleeson et al., 2013). Between-group differences on vocational
30 status will be examined using logistic regression. Patterns of missing data and missing data
31 mechanisms will be investigated using two approaches; firstly, Little's missing completely at random
32 (MCAR) test will be used to assess the degree to which the data are likely to meet the MCAR
33 mechanism; secondly, prediction of missingness at each of the assessment points will be undertaken
34 using binary logistic regression, with a range of baseline sociodemographic, clinical, and
35 psychopathology variables used to predict the presence or absence of a particular assessment.
36 Likelihood techniques will be used to address missing data. The same statistical models described
37 above will be used to characterise the effects of treatment regimen on grey and white matter
38 volumes. Flexible factorial models will be used to estimate significant within-and between-group
39 activation effects at the whole brain level (using F-tests) to determine the effects of treatment
40 regimen on brain function. A cluster-based permutation approach will be used to identify significant
41 differences satisfying a Family Wise Error rate of .05. Age and sex assigned at birth will be controlled
42 for in all analyses.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Dose reduction in FEP: Study Protocol

Data Safety Monitoring Board

A Data Safety Monitoring Board will be established in accordance with ICH-GCP Guidelines and the NHMRC's 2018 guidelines on DSMBs.

Trial Status

The study commenced enrolling participants in July 2017. Enrolment is continuing at the time of manuscript submission. The report of the study findings is expected in 2024.

Funding: The study is funded by an National Health Medical Research Council (NHMRC) Project grant (APP 1102394) from the Commonwealth of Australia. Killackey has been funded by an NHMRC CDF II Fellowship (APP1051891) and a Fellowship from the BB & A Miller Foundation. Alvarez-Jimenez was supported by a Career Development Fellowship (APP1082934) from the National Health and Medical Research Council. Nelson is funded by an NHMRC Senior Research Fellowship. Bendall is funded by a Fellowship from the McClusker Charitable Foundation. Allott is funded by a Ronald Philip Griffiths Fellowship, The University of Melbourne.

1. Addington, J., Killackey, E., & Marulanda, D. (In Press). Early Psychosis Services. In A. R. Yung & P. D. AR. McGorry (Eds.), PD, eds. *Youth Mental Health: A Preventive Approach to Mental Disorders in Young People*. Melbourne: IP Communications; In Press.
- Almond, S., Knapp, M., Francois, C., Toumi, M., & Brugha, T. (2004). Relapse in schizophrenia: costs, clinical outcomes and quality of life. *British Journal Of Psychiatry*, 184, 346-351.
- Alvarez-Jimenez, M., Gleeson, J. F., Henry, L. P., Harrigan, S. M., Harris, M. G., Killackey, E., . . . McGorry, P. D. (2012). Killackey E, Allott K. Utilising Individual Placement and Support to address unemployment and low education rates among individuals with psychotic disorders. *Australian and New Zealand Journal of Psychiatry*. 2013;47(6):521-523.
3. Waghorn G, Saha S, Harvey C, et al. 'Earning and learning' in those with psychotic disorders: The second Australian national survey of psychosis. *Australian and New Zealand Journal of Psychiatry*. 2012;46(8):774-785.

Dose reduction in FEP: Study Protocol

4. [Horan WP, Subotnik, K. L., Snyder, K. S. & Nuechterlein, K. H. Do recent-onset schizophrenia patients experience a "social network crisis"? . *Psychiatry*. 2006;69:115-129.](#)
5. [Harvey C, Killackey E, Groves A, Herrman H. A place to live: housing needs for people with psychotic disorders identified in the second Australian survey of psychosis. *Australian and New Zealand Journal of Psychiatry*. 2012;46:840-850.](#)
6. [Morgan V, McGrath J, Jablensky A, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. *Psychological medicine*. Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. *Psychological medicine*, 42\(3\), 595-606. doi:10.1017/S0033291711001504 . 2013:1-14.](#)
7. [Morgan VA, Waterreus A, Jablensky A, et al. People Living with Psychotic Illness 2010. In: Department of Health and Ageing, ed. Canberra: Commonwealth of Australia; 2011.](#)
8. [Alvarez-Jimenez, M., O'Donoghue, B., Thompson, A., Gleeson, J. F., Bendall, S., Gonzalez-Blanch, C., ... McGorry, P. D. \(2016\). A, et al. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era. *CNS Drugs*, 2016;30\(5\):357-368. doi:10.1007/s40263-016-0331-x](#)
9. [Ramsay CE, Broussard B, Goulding SM, et al. Life and treatment goals of individuals hospitalized for first-episode nonaffective psychosis. *Psychiatry research*. 2011;189\(3\):344-348.](#)
10. [Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial. *JAMA Psychiatry*. 2013;70\(9\):913-920.](#)
11. [Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. *Journal of Clinical Psychiatry*. 2007;68\(5\):654-661.](#)
12. [Correll CU, Rubio JM, Kane JK. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? Alvarez-Jimenez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., & Gleeson, J. F. \(2011\). Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis. *Schizophr Bull*, 37\(3\), 619-630. *World Psychiatry* 2018;17:149-160.](#)
13. [Program EPGWGaENS. *Australian Clinical Guidelines for Early Psychosis, 2nd edition update*. Melbourne: Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne.;2016.](#)
14. [Andreasen, N., Carpenter, W., Kane, J., Lasser, R., Marder, S., & Weinberger, D. \(2005\). Remission in schizophrenia: proposed criteria and rationale for consensus. *American Journal of Psychiatry*, 2005;162:441-449.](#)
[Andreasen, N. C. \(1984\). *Scale for Assessment of Negative Symptoms \(SANS\)*. Iowa City: University of Iowa.](#)

Formatted: Font: (Default) Calibri, 12 pt, Not Italic, English (U.S.)

Formatted: Font: (Default) Calibri, 12 pt, Not Italic, English (U.S.)

Dose reduction in FEP: Study Protocol

- Andreasen, N. C., Liu, D., Ziebell, S., Vora, A., & Ho, B. C. (2013). Knapp M, Patel A, Curran C, et al. Supported employment: cost-effectiveness across six European sites. *World Psychiatry*. 2013;12(1):60-68.
16. Ascher-Svanum H, Zhu BJ, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. *Bmc Psychiatry*. 2010;10.
17. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. *British Journal of Psychiatry*. 2004;184:346-351.
18. Iyer SN, Mangala R, Anitha J, Thara R, Malla AK. An examination of patient-identified goals for treatment in a first-episode programme in Chennai, India. *Early Intervention in Psychiatry*. 2011;5(4):360-365.
19. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. *Am J Psychiatry*. 2013;170(6):609-615. doi:10.1176/appi.ajp.2013.12050674
- Ascher-Svanum, H., Zhu, B. J., Faries, D. E., Salkever, D., Slade, E. P., Peng, X. M., & Conley, R. R. (2010). The cost of relapse and the predictors of relapse in the treatment of schizophrenia. *BMC psychiatry*, 10. doi:2 10.1186/1471-244x-10-2
- Association, A. P. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.
- Bola, J. R., & Mosher, L. R. (2002). Sohlner N, Adams BG, Barnes DM, Cohen GH, Prins SJ, Schwartz S. Weighing the Evidence for Harm From Long-Term Treatment With Antipsychotic Medications: A Systematic Review. [Article]. *American Journal of Orthopsychiatry*. 2016;86(5):477-485.
21. Chen EYH, Hui CLM, Lam MML, et al. At issue: Predicting drug-free treatment response in acute psychosis from the Soteria project. *Schizophrenia Bulletin*, 28(4), 559-575.
- Bowie, C. R., McLaughlin, D., Carrion, R. E., Auther, A. M., & Cornblatt, B. A. (2012). Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis. *Schizophrenia research*, 137(1-3), 110-117. doi:10.1016/j.schres.2012.02.008
- Carpenter, W. T., Jr., Appelbaum, P. S., & Levine, R. J. (2003). The Declaration of Helsinki and clinical trials: A focus on placebo-controlled trials in schizophrenia. *American Journal of Psychiatry*, 160(2), 356-362.
- Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., ... Honer, W. G. (2010). Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. *British medical journal, Medical Journal*. 2010;341. doi:e4024
22. Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. *Schizophrenia research*. 2013;148(1-3):117-121.
23. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. *Bmc Psychiatry*. 2013;13.
24. Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I. A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo. *Journal of Clinical Psychopharmacology*. 2011;31(6):698-704.

Formatted: Font: (Default) Calibri, 12 pt, Not Italic, English (U.S.)

Formatted: Space After: 0 pt

Formatted: Font: Not Italic

Dose reduction in FEP: Study Protocol

25. [Grundy S, Brewer H, Jr., Cleeman J, Smith S, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. . 10.1136/bmj.c4024 Circulation 2004; 109\(Jan 27\):433-438.](#)
26. [Coldham, E. L., EL, Addington, J., & Addington, D. \(2002\). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica, 2002;106\(4\):286-290.](#)
27. [Correll, C. U., Rubio, J. M., & Kane, J. K. \(2018\). What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry, 17, 149-160.](#)
28. [Whale R, Harris M, Kavanagh C, et al. Effectiveness of antipsychotics used in first episode psychosis: a naturalistic cohort study. BJPsych Open. 2016;2:323-329.](#)
29. [De Hert, M., Correll, C., Bobes, J., Cetkovich-Bakmas, M., Cohen, D., Asai, I., Leucht, S. \(2011\). J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World psychiatry : official journal of the World Psychiatric Association, 2011;10\(1\):52-77.](#)
30. [Subotnik KL, Nuechterlein KH, Ventura J, Marder S. Response to Gordon and Green Letter. American Journal of Psychiatry. 2011;168\(9\):987-988.](#)
31. [Olfson M, Gerhard T, Huang C, Crystal S, Stroup T. Premature mortality among adults with schizophrenia in the united states. JAMA Psychiatry. 2015:1-10.](#)
32. [Hage A, Weymann L, Bliznak L, Marker V, Mechler K, Dittmann RW. Non-adherence to Psychotropic Medication Among Adolescents - A Systematic Review of the Literature. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. 2018;46\(1\):69-78.](#)
33. [Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis. Schizophr Bull. 2011;37\(3\):619-630.](#)
34. [Bola JR, Mosher LR. At issue: Predicting drug-free treatment response in acute psychosis from the Soteria project. Schizophrenia Bulletin. 2002;28\(4\):559-575.](#)
35. [Lesh A, T, Tanase C, Geib B, R, et al. A Multimodal Analysis of Antipsychotic Effects on Brain Structure and Function in First-Episode Schizophrenia. JAMA Psychiatry. 2015.](#)
36. [Bowie CR, McLaughlin D, Carrion RE, Auther AM, Cornblatt BA. Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis. Schizophrenia research. 2012;137\(1-3\):110-117.](#)
37. [Lui S, Li T, Deng W, et al. Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. Archives of General Psychiatry 2010;67\(8\):783-792.](#)
38. [Sarpal D, K, Robinson D, G, Lencz T, et al. Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia. JAMA Psychiatry. 2015;72\(1\):5-13.](#)
39. [Radua J, Borgwardt A, Crescini D, et al. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neuroscience and Biobehavioral Reviews. 2012;36:2325-2333.](#)
40. [Husa AP, Rannikko I, Moilanen J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An](#)

Formatted: Font: Not Italic

Formatted: Font: Not Italic

Formatted: Font: Italic

Dose reduction in FEP: Study Protocol

- observational 9-year follow-up study. *Schizophrenia research* Emsley, R., Chiliza, B., & Asmal, L. (2013). The evidence for illness progression after relapse in schizophrenia. *Schizophrenia research*, 148(1-3), 117-121. doi:10.1016/j.schres.2013.05.016
- Emsley, R., Chiliza, B., Asmal, L., & Harvey, B. H. (2013). The nature of relapse in schizophrenia. *BMC psychiatry*, 13. doi:50
- 10.1186/1471-244x-13-50
- . 2014;158(1-3):134-141.
40. Faber, G., Smid, H. G., HG, Van Gool, A. R., AR, Wiersma, D., & Van Den Bosch RJ. The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. R. J. (2012). The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. *Eur Psychiatry*, 2012;27(4,):275-280. doi:10.1016/j.eurpsy.2011.02.003
41. Weickert TW, Mattay VS, Das S, et al. Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease. *Schizophrenia research*. 2013;149(1-3):162-166.
42. Knowles EEM, David AS, Reichenberg A. Processing Speed Deficits in Schizophrenia: Reexamining the Evidence. *American Journal of Psychiatry*. 2010;16(7):828-835.
43. Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. *Journal of Clinical Psychopharmacology*. 2001;21(5):479-483.
44. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of Cognitive Performances During a Placebo Period and an Atypical Antipsychotic Treatment Period in Schizophrenia: Critical Examination of Confounds. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2003;28:1497-1500.
45. Gleeson JF, Cotton SM, Alvarez-Jimenez M, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. *J Clin Psychiatry*. 2009;70(4):477-486.
46. McGorry PD, Alvarez-Jimenez M, Killackey E. Antipsychotic medication during the critical period following remission from first-episode psychosis. Less is more *JAMA Psychiatry*. 2013.
47. Alvarez-Jimenez M, Gleeson JF, Henry LP, et al. Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. *Psychological medicine* First MB, W. J., Karg RS, Spitzer RL (2015). *Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)*. Arlington, VA: American Psychiatric Association. . 2012;42(3):595-606.
48. Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., ... Aravagiri, M. (2001). KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. *American Journal of Psychiatry*, 2001;158(11,):1835-1842.
- Gleeson, J. F., Cotton, S. M., Alvarez Jimenez, M., Wade, D., Gee, D., Crisp, K., ... McGorry, P. D. (2009). 49. McGorry P. Issues for DSM-V: Clinical staging: A heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. *American Journal of Psychiatry*. 2007;164(6):859-860.

Formatted: Font: Not Italic

Formatted: Font: Italic

Formatted: Font: Not Italic

Dose reduction in FEP: Study Protocol

50. ~~Carpenter WT, Jr., Appelbaum PS, Levine RJ. The Declaration of Helsinki and clinical trials: A focus on placebo-controlled trials in schizophrenia. *American Journal of Psychiatry*. 2003;160(2):356-362.~~
51. ~~Killackey E, Jackson HJ, McGorry PD. Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. *J Clin Psychiatry*. 2008;70(4):477-486. *Br J Psychiatry*. 2008;193(2):114-120.~~
52. ~~Gleeson, J. F. M., JFM, Cotton, S. M., SM, Alvarez-Jimenez, M., Wade, D., Gee, D., Crisp, K., ... McGorry, P. D. (2013). M, et al. A Randomized Controlled Trial of Relapse Prevention Therapy for First-Episode Psychosis Patients: Outcome at 30-Month Follow-Up. *Schizophrenia Bulletin*, 2013;39(2):436-448. doi:10.1093/schbul/sbr165~~
- ~~Goldman, H. H., Skodol, A. E., & Lave, T. R. (1992). Revising Axis V for DSM-IV: A review of measures of social functioning. *American Journal of Psychiatry*, 149(9), 1148-1156.~~
- ~~Grundy, S., Brewer, H., Jr., Cleeman, J., Smith, S., Jr., & Lenfant, C. (2004). Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation*, 109(Jan 27), 433-438.~~
- ~~Hage, A., Weymann, L., Bliznak, L., Marker, V., Mechler, K., & Dittmann, R. W. (2018). Non-adherence to Psychotropic Medication Among Adolescents—A Systematic Review of the Literature. *Z Kinder Jugendpsychiatr Psychother*, 46(1), 69-78. doi:10.1024/1422-4917/a000505~~
- ~~Harvey, C., Killackey, E., Groves, A., & Herrman, H. (2012). A place to live: housing needs for people with psychotic disorders identified in the second Australian survey of psychosis. *Australian and New Zealand Journal of Psychiatry*, 46, 840-850.~~
- ~~Horan, W. P., Subotnik, K. L., Snyder, K. S. & Nuechterlein, K. H. (2006). Do recent-onset schizophrenia patients experience a "social network crisis"? *Psychiatry*, 69, 115-129. doi:https://doi.org/10.1521/psyc.2006.69.2.115~~
- ~~Husa, A. P., Rannikko, I., Moilanen, J., Haapea, M., Murray, G. K., Barnett, J., ... Jaaskelainen, E. (2014). Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia—An observational 9-year follow-up study. *Schizophrenia research*, 158(1-3), 134-141. doi:10.1016/j.schres.2014.06.035~~
- ~~Iyer, S. N., Mangala, R., Anitha, J., Thara, R., & Malla, A. K. (2011). An examination of patient-identified goals for treatment in a first-episode programme in Chennai, India. *Early intervention in psychiatry*, 5(4), 360-365.~~
- ~~Keefe, R. S., Harvey, P. D., Goldberg, T. E., Gold, J. M., Walker, T. M., Kennel, C., & Hawkins, K. (2008). Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). *Schizophr Res*, 102(1-3), 108-115. doi:10.1016/j.schres.2008.03.024~~
- ~~Killackey, E., & Allott, K. (2013). Utilising Individual Placement and Support to address unemployment and low education rates among individuals with psychotic disorders. *Australian and New Zealand Journal of Psychiatry*, 47(6), 521-523.~~
- ~~Killackey, E., Jackson, H. J., & McGorry, P. D. (2008). Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. *The British*~~

Formatted: Font: Not Italic

Dose reduction in FEP: Study Protocol

- journal of psychiatry : the journal of mental science*, 193(2), 114-120.
doi:10.1192/bjp.bp.107.043109
- Klemp, M., Tvette, I. F., Skomedal, T., Gaasemyr, J., Natvig, B., & Aursnes, I. (2011). A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo. *J Clin Psychopharmacol*, 31(6), 698-704. doi:10.1097/JCP.0b013e31823657d9
- Knapp, M., Patel, A., Curran, C., Latimer, E., Catty, J., Becker, T., ... Burns, T. (2013). Supported employment: cost-effectiveness across six European sites. *World psychiatry : official journal of the World Psychiatric Association*, 12(1), 60-68. doi:10.1002/wps.20017
- Lesh, A., T, Tanase, C., Geib, B., R, Niendam, T., A, Jong, Y., H., Minzenberg, M., J., ... Carter, C., S (2015). A Multimodal Analysis of Antipsychotic Effects on Brain Structure and Function in First-Episode Schizophrenia. *JAMA Psychiatry*. doi:10.1001/jamapsychiatry.2014.2178
- Lui, S., Li, T., Deng, W., Jiang, L., Wu, Q., Tang, H., ... Gong, Q. (2010). Short-term effects of antipsychotic treatment on cerebral function in drug-naïve first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. *Archives of General Psychiatry*, 67(8), 783-792. doi:10.1001/archgenpsychiatry.2010.84
- McGorry, P. (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. *Australian and New Zealand Journal of Psychiatry*, 39(1-2), 1-30.
- McGorry, P. (2007). Issues for DSM-V: Clinical staging: A heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. *American Journal of Psychiatry*, 164(6), 859-860.
- McGorry, P. D., Alvarez-Jimenez, M., & Killackey, E. (2013). Antipsychotic medication during the critical period following remission from first-episode psychosis: Less is more. *JAMA Psychiatry*. doi:10.1001/jamapsychiatry.2013.264.
- Morgan, V., McGrath, J., Jablensky, A., Badcock, J., Waterreus, A., Bush, R., ... Galletly, C. (2013). Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. *Psychological medicine*, 1-14.
- Morgan, V. A., Waterreus, A., Jablensky, A., Mackinnon, A., McGrath, J. J., Carr, V., ... Saw, S. (2011). *People Living with Psychotic Illness 2010*. Canberra: Commonwealth of Australia.
- National Collaborating Centre for Mental Health. (2014). *Psychosis and Schizophrenia in adults: The NICE guideline on treatment and management. Updated edition 2014*. London: National Institute for Health and Care Excellence.
- Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. (2015). Premature mortality among adults with schizophrenia in the United States. *JAMA Psychiatry*, 1-10. doi:10.1001/jamapsychiatry.2015.1737
- ORYGEN Youth Health. (2010). *The Australian Clinical Guidelines for Early Psychosis*. Melbourne: ORYGEN Youth Health Research Centre.
- Overall, J. E., & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. *Psychiatric Reports*, 10, 799-812.
- Program, E. P. G. W. G. a. E. N. S. (2016). *Australian Clinical Guidelines for Early Psychosis, 2nd edition update*. Retrieved from Melbourne:

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Dose reduction in FEP: Study Protocol

- Radua, J., Borgwardt, A., Crescini, D., Mataix-Cols, A., Meyer-Lindenberg, A., McGuire, P. K., & Fusar-Poli, P. (2012). Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. *Neuroscience and Biobehavioral Reviews*, *36*, 2325-2333. doi:10.1016/j.neubiorev.2012.07.012
- Ramsay, C. E., Broussard, B., Goulding, S. M., Cristofaro, S., Hall, D., Kaslow, N. J., . . . Compton, M. T. (2011). Life and treatment goals of individuals hospitalized for first episode nonaffective psychosis. *Psychiatry research*, *189*(3), 344-348. doi:10.1016/j.psychres.2011.05.039
- Sarpal, D., K., Robinson, D., G., Lencz, T., Argyelan, M., Ikuta, T., Karlsgodt, K., . . . Szeszko, P., R. (2015). Antipsychotic Treatment and Functional Connectivity of the Striatum in First Episode Schizophrenia. *JAMA Psychiatry*, *72*(1), 5-13. doi:10.1001/jamapsychiatry.2014.1734
- Sohler, N., Adams, B. G., Barnes, D. M., Cohen, G. H., Prins, S. J., & Schwartz, S. (2016). Weighing the Evidence for Harm From Long Term Treatment With Antipsychotic Medications: A Systematic Review. [Article]. *American Journal of Orthopsychiatry*, *86*(5), 477-485.
- Subotnik, K. L., Nuechterlein, K. H., Ventura, J., & Marder, S. (2011). Response to Gordon and Green Letter. *American Journal of Psychiatry*, *168*(9), 987-988. doi:10.1176/appi.ajp.2011.11030442r
53. Thompson, A., Singh, S., & Birchwood, M. (2016). Views of early psychosis clinicians on discontinuation of antipsychotic medication following symptom remission in first episode psychosis. *Early intervention in psychiatry*, *2016*,10(4), 355-361.
54. National Collaborating Centre for Mental Health. *Psychosis and Schizophrenia in adults: The NICE guideline on treatment and management. Updated edition 2014*. London: National Institute for Health and Care Excellence; 2014.
55. ORYGEN Youth Health. *The Australian Clinical Guidelines for Early Psychosis*. Melbourne: ORYGEN Youth Health Research Centre; 2010.
56. Association AP. *Diagnostic and statistical manual of mental disorders 5th ed*. Arlington, VA: American Psychiatric Publishing; 2013.
57. First MB WJ, Karg RS, Spitzer RL *Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)*. Arlington, VA: American Psychiatric Association; 2015.
58. Ventura, J., Lukoff, D., Nuechterlein, K. H., Liberman, R. P., Green, M. F., & MF, Shaner, A. (1993). *Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0). Scales, Anchor Points, and Administration Manual*. West Los Angeles: UCLA Department of Psychiatry and Behavioral Sciences.; 1993.
- Waghorn, G., Saha, S., Harvey, C., Morgan, V. A., Waterreus, A., Bush, R., . . . McGrath, J. J. (2012). 59. Goldman HH, Skodol AE, Lave TR. *Revising Axis V for DSM-IV: A review of measures of social functioning*. *American Journal of Psychiatry*. 1992;149(9):1148-1156.
60. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychiatric Reports*. 1962;10:799-812.
61. Andreasen NC. *Scale for Assessment of Negative Symptoms (SANS)*. Iowa City: University of Iowa; 1984.

Formatted: Font: Not Italic

Formatted: Font: Italic

Formatted: Font: Italic

Dose reduction in FEP: Study Protocol

62. [Keefe RS, Harvey PD, Goldberg TE, et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia \(BACS\). *Schizophrenia research*. 2008;102\(1-3\):108-115.](#)
- ~~'Earning and learning' in those with psychotic disorders: The second Australian national survey of psychosis. *Australian and New Zealand Journal of Psychiatry*, 46(8), 774-785. doi:10.1177/0004867412452015~~
- ~~Weickert, T. W., Mattay, V. S., Das, S., Bigelow, L. B., Apud, J. A., Egan, M. F., . . . Goldberg, T. E. (2013). Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease. *Schizophrenia research*, 149(1-3), 162-166. doi:10.1016/j.schres.2013.06.028~~
- ~~Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013). Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction, Discontinuation or Maintenance Treatment Strategy: Long term Follow-up of a 2-Year Randomized Clinical Trial. *JAMA Psychiatry*, 70(9), 913-920. doi:10.1001/jamapsychiatry.2013.19~~
- ~~Wunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007). Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. *Journal of Clinical Psychiatry*, 68(5), 654-661.~~

Dose reduction in FEP: Study Protocol

Table 1

Outline of Schedule of Assessments

	Visit 1 Baseline		Visit 2	Visit 3		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
Informed Consent ⁴	X					
Inclusion/Exclusion Criteria	X					
Demographics	X		X	X		X
Medical & Psychiatric History		X				
Pregnancy (urine) ⁵	X			X		X

¹ Core Baseline assessments may be conducted over a number of visits to allow for 'real-world' scenarios however, must be completed prior to randomisation.

² Non-Core Component Baseline assessments may be conducted over a number of visits to allow for 'real-world' scenarios and can be completed up to 3 weeks after randomisation.

³ Telephone contact every 6 weeks from Month 9-24 to check discontinuation/withdrawal criteria.

⁴ Informed consent can be obtained up to 21 days prior to baseline.

⁵ In addition to conducting urine pregnancy tests at each baseline and 24-month assessments, participants will also be asked to indicate whether they are pregnant or not during 9-month, 15-month assessments and telephone follow-ups.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
Concomitant Med. Review ⁶		X	X	X	X	X
Treatment Allocation						
Randomisation	X					
Diagnosis						
SCID5-RV (Modules A & B)	X			X		X
Intervention						
Participants in DRS+ ⁷						
EBIRT ⁸	←—————→			←-----→ Post intervention Follow up		

⁶ To maintain blinding of RAs, EBIRT clinicians will review medication adherence weekly (every second session) during the EBIRT intensive phase and every session during the EBIRT maintenance phase. EBIRT clinicians will also check concomitant medications every 6 weeks during the intervention phase (up to minimum of 15 months).

⁷ Reduce antipsychotic medication dose by 25% every month for 3 months as clinically indicated.

⁸ EBIRT intensive phase: Twice weekly individual therapy sessions to month 9, maintenance/monitoring phase 4-6 weeks individual therapy for a minimum of 6 months. A checklist recording details and items covered in of the EBIRT (CBT) Session will be completed every session by the Clinician and entered directly into the eCRF. The IPS Worker will also complete a checklist recording items covered in every session and enter this in to the eCRF. This data will be used to assess fidelity of EBIRT.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
Medication Compliance						
Clinician's compliance rating ⁵		X	X	X		
MARS ⁵		X	X	X		X
Medication side effects						
LUNTERS		X	X	X		X
Symptomatology						
BPRS ⁹	X		X	X	X	X
SANS		X	X	X		X
DASS-21		X	X	X	X	X
CDSS		X	X	X		X
IPASE		X	X	X		X
Functioning & Quality of Life						
SOFAS ⁸		X	X	X	X	X
Vocational functioning		X	X	X	X	X

⁹ In addition to assessment time-points and telephone follow-up, the BPRS and SOFAS will be measured weekly during the intensive phase and at therapy sessions during the maintenance phase for purposes of discontinuation criteria.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
WHOQoL-BREF		X	X	X		X
ULCAL5		X	X	X		X
MHCS		X	X	X		X
The Self-efficacy Scale		X	X	X		X
BPNS		X	X	X		X
Daily functioning and affect						
SEMA ¹⁰		X	X	X		X
Pre-morbidity and illness						
NOS		X				
Trauma						
CTQ		X				
Metabolic monitoring						
Clinical Bloods ¹¹		X	X	X		X

¹⁰ SEMA will be used to deliver electronic surveys (to be administered directly after the baseline and follow up assessments (visits 1-4) at 8 time points per day in the waking hours of each participant for a period of 7 days. Only participants who have smartphones will complete these surveys.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
Blood pressure, height, weight and waist circumference ¹²		X	X	X		X
Substance Use						
AUDIT		X	X	X		X
ASSIST		X	X	X		X
Neurocognitive						
WRAT-4		X				
BACS		X	X	X		X
ER-40		X	X	X		X
The Hinting Task		X	X	X		X

¹¹ Clinical bloods will involve testing for **fasting glucose**, haemoglobin A_{1c}, **and lipid levels** (fasting triglycerides and fasting total HL cholesterol). Clinical Bloods assessment to be completed within two weeks of randomisation and within two weeks of Visits 2 to 4.

¹² Blood pressure, height, weight and waist circumference will also be measured at approximately 12, 18, and 21 months in addition to study visits. These will be measured by study RAs.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
PAL		X	X	X		X
Edinburgh Handedness Inventory		X				
NSSR		X	X	X		X
PDQ		X	X	X		X
AES		X	X	X		X
Structural and functional Imaging						
Shoulder and Hip width ¹³		X				
MRI ¹⁴		X	X	X		X

¹³ Eligibility assessment for MRI scan

¹⁴ MRI assessment to be completed within two weeks of randomisation and within two weeks of Visits 2 to 4.

Dose reduction in FEP: Study Protocol

Table 22 [Temporary Pause from DRS+](#)


1.	Increases from 3 (mild) or below to ratings of 6 or 7 (severe or very severe) on any one of the following 3 BPRS ⁴⁹ items: (i) unusual thought content, (ii) hallucinations, and (iii) conceptual disorganisation, with a duration criterion of 1 week;
2.	Significant psychotic exacerbations defined by an increase from 3 or below (for at least 1 month) on all the BPRS ⁴⁹ 3 scales followed by a score of 5 (moderate) on any of the 3-items plus a 2-point increase on one of the other scales (again with the addition of a duration criterion of 1 week) or a rating of 5 on any one of the 3 scales for at least 1 month.
3.	An increase in suicidality as defined by a score of 5 or more on the BPRS ⁴⁹ Suicidality subscale (i.e., many fantasies about suicide, specific suicide plan, non-lethal attempt) for a duration of at least 1 week.
AND	
4.	A significant decrease in overall functioning as defined by a 20-point drop in SOFAS score from the baseline score, maintained for one month.

Formatted Table

Dose reduction in FEP: Study Protocol

<u>OR</u>	
5.	If the above criteria are not met but the participant is considered by their treating clinical team to have significantly deteriorated in relation to psychotic symptoms compared to baseline, and clinical response is deemed necessary, they may also be temporarily paused from the DRS+.


Table 3



Reduce Intervention Timeline

Formatted: Font: (Default) +Body (Calibri), 11 pt, Highlight

Dose reduction in FEP: Study Protocol



Formatted: Font: (Default) +Body (Calibri), 11 pt, Highlight

1
2
3 Can anti-psychotic dose reduction lead to better functional recovery in first episode
4 psychosis? A randomised controlled trial of anti-psychotic dose reduction. The Reduce Trial:
5
6 Study Protocol
7
8
9
10

11 Amber Weller^{1,2}, John Gleeson⁵, Mario Alvarez-Jimenez^{1,2}, Patrick McGorry^{1,2}, Barnaby
12 Nelson^{1,2}, Kelly Allott^{1,2}, Sarah Bendall^{1,2}, Cali Bartholomeusz^{1,2}, Peter Koval⁷, Susy Harrigan⁶,
13 Brian O'Donoghue^{1,2,4}, Alex Fornito⁸, Christos Pantelis^{9,10}, G. Paul Amminger^{1,2}, Aswin
14 Ratheesh^{1,2,4}, Andrea Polari^{2,4}, Stephen J Wood^{1,2,3}, Kristi van-der-EL^{1,2}, Carli Ellinghaus^{1,2},
15 Jesse Gates⁴, Jessica O'Connell⁴, Marianne Mueller^{1,2}, Lex Wunderink¹¹, Eóin Killackey^{1,2}.
16
17
18
19
20
21
22

23 Correspondence: Eóin Killackey eoin.killackey@orygen.org.au
24

25 ¹Orygen, the National Centre of Excellence in Youth Mental Health
26

27 ²Centre for Youth Mental Health, The University of Melbourne
28

29 ³School of Psychology, University of Birmingham, Edgbaston UK
30

31 ⁴Melbourne Health
32
33

34 ⁵Australian Catholic University
35
36

37 ⁶Centre for Mental Health, School of Population and Global Health, University of Melbourne
38
39

40 ⁷School of Psychological Sciences, University of Melbourne
41
42

43 ⁸Monash Clinical and Imaging Neuroscience, School of Psychological Sciences, Monash
44 University
45

46 ⁹Melbourne Neuropsychiatry Centre
47
48

49 ¹⁰Department of Psychiatry, University of Melbourne
50
51

52 ¹¹Friesland Mental Health Services
53
54
55
56
57
58
59
60

Abstract

Anti-psychotic medication has been the mainstay of treatment for psychotic illnesses for over 60 years. This has been associated with improvements in positive psychotic symptoms and a reduction in relapse rates. However, there has been little improvement in functional outcomes for people with psychosis. At the same time there is increasing evidence that medications contribute to life shortening metabolic and cardio-vascular illnesses. There is also uncertainty as to the role played by anti-psychotic medication in brain volume changes.

Aim: The primary aim of the study is, in a population of young people with first episode psychosis, to compare functional outcomes between an anti-psychotic dose reduction strategy with evidence based intensive recovery treatment (EBIRT) group (DRS+) and an antipsychotic maintenance treatment with EBIRT group (AMTx+) at 24-months follow up.

Methods: Our single-blind randomized controlled trial, within a specialist early psychosis treatment setting, will test the whether the DRS+ group leads to better vocational and social recovery than, the AMTx+ group over a 2-year period in 180 remitted first episode psychosis patients. Additionally, we will examine the effect of DRS+ vs AMTx+ on physical health, brain volume and cognitive functioning. This study will also determine whether the group receiving DRS+ will be no worse off in terms of psychotic relapses over 2 years follow up.

Results: This paper presents the protocol, rationale and hypotheses for this study which commenced recruitment in July 2017.

Conclusion: This study will provide evidence as to whether an antipsychotic dose-reduction recovery treatment leads to improved functioning and safer outcomes in first episode psychosis patients. In addition, it will be the first controlled experiment of the effect of exposure to antipsychotic maintenance treatment on brain volume changes in this population.

Key words:

First-episode psychosis

Functional recovery

Dose reduction

Anti-psychotic medication

Protocol

Introduction

It is over 65 years since antipsychotic medications were introduced and became the mainstay of treatment for psychotic illnesses. There has undoubtedly been many benefits of their use in the control of symptoms, particularly positive symptoms of psychotic illness, and the reduction of relapse rates¹. Despite this, and even with the introduction of second-generation antipsychotic medication there has been little indication that people with psychotic illness have returned to functional roles in any great number. For example, people diagnosed with psychotic illnesses² are less likely to complete their secondary education³ and unemployment remains a highly prevalent problem associated with the disorder. Loneliness is also a significant issue for young people with psychosis, so much so that the onset of psychosis has been characterised as a social network crisis which is not ameliorated by current interventions⁴. In a range of other functional domains, housing security,⁵ physical health⁶, social relationships and engagement in community⁷, people with psychotic illnesses have worse outcomes than the general population. Antipsychotic medications are effective at addressing the symptoms of illness but have little to no success at addressing many of the associated problems of the illness⁸. Yet, it is these problems that people living with psychosis most want addressed⁹.

Data from papers published over the last 11 years^{10,11} have raised the question of how the best balance or “sweet-spot” is struck between exposure to antipsychotic medication, symptomatic improvement, the minimisation of iatrogenic harm and maximising functional recovery¹². The study described in this paper seeks to answer this question.

Background

After remission from acute symptoms of psychosis is achieved, most treatments for psychosis have focussed upon the prevention of psychotic relapse^{13,14}. Relapse prevention is a worthy clinical goal, due to the potential for distress and other risks associated with acute symptoms, the direct cost of multiple hospital visits associated with relapse¹⁵, as well as relapsing courses of psychosis being up to 4 times more expensive than non-relapsing courses^{16,17}. Less focus has been placed on improving social and vocational functioning despite these being the primary goals of people who experience psychosis^{9,18}. For this reason, functional recovery of people with psychotic illness warrants further attention. In this context we define functional recovery to mean- age appropriate vocational functioning, having social outlets, such as friends beyond one’s immediate family and participation in one’s community through such activities as voting.

The impact of antipsychotic maintenance treatment

Current evidence based treatment guidelines recommend antipsychotic maintenance treatment for 2-5 years after a First Episode of Psychosis (FEP)¹³, followed by annual review¹³. In reality, maintenance treatment can continue for decades¹⁹, partly due to the lack of clarity and evidence around how long individuals should receive antipsychotic treatment^{13,20}. The goal of current guidelines is to prevent symptomatic relapse rates in FEP clients^{21,22}. Arguments in favour of ongoing maintenance treatment are that: in the absence of medication, risk of relapse rises significantly, episodes of relapse tend to become longer after the initial episode²²; response to medication takes longer; and approximately 14% at each relapse will not respond to medication²³. While maintenance treatment is generally successful at treating positive psychotic symptoms²⁰, the associated side-effects of antipsychotic medication can be a case of significant harm. These side-effects include weight gain^{24,25}, sexual dysfunction¹³ and possible contribution to poor functional recovery in¹⁰ people with positive symptom remission. These associated side-effects can result in poor medication adherence²⁶. Adherence to antipsychotic medication is poor in FEP; around 60% of them have either non adherence or poor adherence²⁷. Further implications of maintenance treatment include metabolic disturbances which lead to increased risks for cardiovascular disease and diabetes and the potential for a 20-30 year reduction in life expectancy in people with psychosis^{28,29,30}. Metabolic and cardiovascular illness, in large part due to antipsychotic medication²⁸, accounts for the majority of this mortality.³¹

In addition, maintenance treatment studies³ and meta-analyses³² over the last 10 years have found a relationship between exposure to antipsychotic medication and changes in brain volume. Recent cross-sectional evidence indicates that antipsychotic medications may produce reductions in grey and white matter volumes^{32,33}. One study in particular found medicated FEP patients to display significant cortical thinning in the dorsolateral prefrontal and temporal cortices when compared to unmedicated FEP patients, who had cortical thickness measures similar to controls³⁴. Moreover, a 7-year longitudinal neuroimaging study in FEP showed that loss of brain tissue occurs at the rate of 0.56 cubic centimetres in patients receiving an average of 4mg/day of haloperidol (dose equivalent) over a 1- year period¹⁹. Intensity in dose years of antipsychotic treatment was associated with reductions in total cerebral volume as well as frontal lobe and white matter volumes. However, without a control group this study could not establish whether brain volume reductions are a direct consequence of maintenance treatment or are accounted for by other illness-related factors. Given that early psychosis is associated with significant loss of grey matter volume over time relative to healthy controls³⁵, there is a possibility that medication discontinuation could reduce this loss, or

1
2
3 preserve brain changes such that they are comparable to neurotypical same-age peers. Further,
4 some evidence suggests that antipsychotic treatment may alter cerebral function in FEP and the
5 impact of a dose reduction strategy on functional connectivity of resting-state neural networks is
6 currently unknown^{34,36-38}. Additionally, cognitive function may be adversely affected by maintenance
7 treatment. Three naturalistic studies in prodromal and established schizophrenia groups show a
8 relationship between level of exposure to antipsychotic medication and decline in cognitive function
9 over time³⁹⁻⁴¹. Furthermore, meta-analytic evidence suggests that the processing speed impairment
10 observed in psychotic disorders is significantly associated with chlorpromazine equivalent daily
11 dose.⁴² As symptom intensity or persistence may confound the relationship between cognitive
12 performance and antipsychotic dose, randomised controlled trials are required.

13
14
15
16
17
18 Two small double-blind placebo-controlled crossover studies of inpatients with schizophrenia (N=27
19 and N=19, respectively) found that antipsychotic medication was associated improved cognitive
20 performance compared with placebo^{43,44}. A recent guided anti-psychotic discontinuation RCT in FEP
21 (N=53) found that cognitive function improved in remitted FEP clients who received guided
22 discontinuation compared with those who received maintenance treatment over a five month follow
23 up period⁴⁰. Previous research has also shown that adherence to high/standard-dose maintenance
24 treatment is associated with poorer psychosocial functioning early in the course of recovery,
25 suggesting that a strong focus on high-dose maintenance medication may interfere with long-term
26 recovery¹⁰. This is also consistent with the follow-up results from the Episode II trial⁴⁵.

27
28
29
30
31
32 A recent critical review also proposed that although anti-psychotic maintenance may be efficacious
33 in mid-term treatment of psychosis, there is a paucity of evidence supporting the efficacy of this
34 treatment approach in the long-term, this supports further investigation of a dose reduction
35 strategy¹².

41 Is dose reduction the answer?

42
43 The negative impacts of long-term maintenance have raised the question of whether dose reduction
44 might be associated with better outcomes for individuals affected by psychotic disorders. Recent
45 evidence showing that functioning improves with a strategy to reduce the dose of antipsychotic
46 medication suggests that functional recovery may be suppressed by long-term exposure to
47 antipsychotic medication^{10,46}. A meta-analysis of RCTs of antipsychotic treatments in FEP clients
48 showed that approximately 40% of placebo-treated FEP clients had not relapsed at 1-year follow
49 up³². Subsequently, one recent RCT revealed that, when compared with continuous maintenance
50 treatment, the discontinuation of maintenance treatment in FEP led to improved recovery at 7 years
51 follow up¹⁰. Importantly, this occurred in the absence of intensive psychosocial treatments that may
52
53
54
55
56
57
58
59
60

1
2
3 hasten improvement of functioning and prevent relapse³². Thus, recovery may be enhanced or
4 hastened if a dose reduction strategy were combined with intensive evidence based psychosocial
5 interventions. These findings suggest that, despite current guidelines, FEP clients may not require
6 maintenance treatment for the initial recommended two-year minimum period to attain recovery
7 and prevent relapse. Indeed, previous research has shown that it is early functional recovery rather
8 than symptomatic recovery that predicts functional recovery at 7.5 years⁴⁷.

9
10
11
12
13 Arguably, patient non-adherence⁴⁸, and planned discontinuation of maintenance treatment both
14 pose risks for relapse after FEP⁴⁷. However, reduction in symptoms does not automatically translate
15 into functional gains. Prioritising relapse prevention without also giving full consideration to the
16 implications for functional recovery may compromise the long-term outcomes most valued by those
17 who experience the illness^{9,49}.

18
19
20
21
22 Management of relapse risk therefore, should be balanced with a focus on functional recovery and
23 the costs of long-term continuous maintenance treatment, including probable enhancement in
24 functioning³². A promising balanced approach to treatment includes a dose reduction strategy,
25 combined with intensive and recovery-focussed psychosocial treatments with vigilant monitoring for
26 early signs of relapse⁵⁰.

27
28
29
30
31 Supplementary to a dose reduction strategy, the use of an evidence-based intensive recovery
32 treatment (EBIRT) should be employed to improve likelihood of overall functional outcomes. In the
33 present study, EBIRT combines two previously trialled interventions. These interventions are
34 Individual Placement and Support (IPS) for vocational recovery and CBT for Relapse Prevention. IPS
35 in addition to specialist FEP treatment has produced significantly better outcomes in gaining
36 employment, hours worked, jobs acquired, and longevity of jobs compared to specialist FEP
37 treatment alone^{45,51}. CBT for relapse prevention combined with specialist FEP treatment when
38 compared with specialist FEP treatment alone⁴⁵, led to a significant reduction in relapse rates at 7-
39 months follow up in FEP clients who met remission on positive symptoms. This effect was sustained
40 at 1 year, and relapse rates were kept to historically low levels beyond this time point (30% at 2.5
41 years)^{45,52}. However, these differences were no longer significant at 30-month follow-up.

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Importantly, 83% of clinicians providing care to people experiencing FEP would support a carefully
monitored dose reduction strategy after patient relapse, and believe this would improve the quality
of life of their clients⁵³. This further supports the acceptability of a dose reduction strategy,
particularly in a FEP setting^{48,54,55}

Aims

The primary aim of the study is to compare functional outcomes between a dose reduction strategy with EBIRT group (DRS+) and an antipsychotic maintenance treatment with EBIRT group (AMTx+) at 24-months follow up.

This study has a range of secondary aims:

1. To compare physical health and metabolic profiles between DRS+ and AMTx+ at 24-months follow up.
2. To compare grey and white matter volume between DRS+ and AMTx+ at 24-months follow up.
3. To compare brain activity during resting-state between DRS+ and AMTx+ at 24 months follow up*.
4. To compare cognitive functioning between DRS+ and AMTx+ at 24-months follow up.
5. To compare remission and relapse rates between DRS+ and AMTx+ at 24-months follow up.

*This is a largely exploratory aim, however based on the limited literature in this area we hypothesis that the DRS+ group would display greater resting state functional connectivity than the AMTx+ and healthy control groups

Primary hypothesis

H1: Remitted FEP patients randomised to DRS+ will achieve superior social and vocational functioning at 24-months follow up, compared with remitted FEP patients randomised to AMTx+.

Secondary hypotheses

H2: Participants randomised to DRS+ will have less reduction in grey and white matter volume than participants randomised to AMTx+ at 24-months follow up.

H3: Degree of antipsychotic exposure will be negatively associated with grey and white matter volume at 24-months follow up. Further, it is expected that change in neural activity during resting state will differ significantly between the DRS+ and AMTx+ groups at 24-months follow-up.

H4: Participants randomised to DRS+ will have better cognitive functioning compared to participants randomised to AMTx+ at 24-months follow up.

H5: Participants in the AMTx group will have experienced fewer relapses at 24-months follow up.

H6: Participants randomised to DRS+ will have significantly better metabolic indices (defined as being within normal parameters) and an improved physical health status at 24-months follow up.

Ethical approval

This study was approved by the Melbourne Health Human Research Ethics Committee (HREC/16/MH/309) in February 2017 and began recruiting participants in July 2017. The trial is registered on the Australian and New Zealand Clinical Trials Registry (12617000870358).

Methodology

Study Design

This study is a single blinded non-placebo randomised controlled trial where research assistants are blinded to treatment allocation.

Study Setting

This study will be conducted at the Early Psychosis Prevention and Intervention Centre (EPPIC), a sub-program of Orygen Youth Health (OYH). OYH is a youth public mental health service in Melbourne for 15 to 25-year-olds (inclusive). EPPIC is a comprehensive specialist early psychosis program that provides outpatient case management, psychosocial intervention and psychiatric treatment. OYH is co-located with Orygen, the National Centre of Excellence in Youth Mental Health and the Centre for Youth Mental Health, The University of Melbourne. EPPIC provides up to 2 years of specialised care after which clients are transferred to another service depending upon the level of care required. A proportion of clients receive follow-up care within primary care settings, while others may continue to require case-management and specialist care and are therefore transferred to the adult mental health service. The Reduce Trial will embed specific resources within EPPIC, including a proportion of one psychiatry registrar position, a Vocational Support Worker and a number of specialist Reduce trial case managers, who will provide the medical oversight, the vocational recovery support and the clinical case management for trial participants, respectively.

Inclusion and Exclusion Criteria

Inclusion and Exclusion Criteria have been designed to reflect 'real-world' characteristics of young people presenting to clinical settings with a FEP.

Inclusion Criteria: (i) Current client of EPPIC; (ii) A confirmed diagnosis of first episode of a DSM 5⁵⁶ psychotic disorder or mood disorder with psychotic features^{56,57}; (iii) Aged 15-25 years (inclusive); (iv) ≥ 3 months of remission on positive symptoms of psychosis in the first year of antipsychotic treatment (participants must currently be taking their prescribed anti-psychotic medication) at EPPIC (a score of ≤ 3 (mild) on the hallucinations, unusual thought disorder, conceptual disorganisation, and suspiciousness subscale items of the Brief Psychiatric Rating Scale (BPRS)⁵⁸ for the past two weeks and a score ≤ 3 on the hallucinations, unusual thought content, conceptual disorganisation,

1
2
3 and suspiciousness subscales of the BRPS⁵⁸ for the past 3 months based on a systematic clinical file
4 review and collateral information collected from the participant's treating team in EPPIC (as
5 needed); (v) Low suicidality defined as a score of 4 or below on the BPRS⁵⁸ sustained for the past 1-
6 month period prior to baseline; (vi) The young person is willing for a caregiver to be informed about
7 the study and will have at least weekly contact with their caregiver; (vii) Ability to provide written
8 informed consent.
9
10

11
12
13 Exclusion Criteria: (i) A documented history of an intellectual disability or IQ <70; (ii) Inability to
14 converse in or read English; (iii) Women who are currently pregnant or breastfeeding; (iv)
15 Neurological disorder (illness of the brain, nerves or spinal cord which could not better explain the
16 presence of psychosis).
17
18

19 20 Recruitment, Consent, and Enrolment

21
22 Participants will be recruited into the trial through a number of strategies- including regular case
23 review discussions between the Reduce research assistant (RA) and EPPIC Consultants, direct
24 referral to Reduce from EPPIC Clinicians and through the RA attending regular EPPIC team meetings
25 to discuss ongoing eligibility of clients nearing three months of psychotic remission. Potential
26 participants are then approached to take part in the trial by either the RA, Reduce registrar or case
27 manager. They are given ample time to consider the option to take part in Reduce and are
28 encouraged to discuss this with their family, local doctor and other supports. Before being enrolled
29 in the study all participants will provide written and informed consent. In the case of minors, their
30 parent or legal guardian will also be required to provide written and informed consent. After the
31 consent process is complete, a Core Baseline assessment is administered by the research assistant.
32 Eligibility is assessed, using the BPRS⁵⁸ and the SCID-RV⁵⁷. Participant medical files and EPPIC clinical
33 files will also be used for collateral information to confirm eligibility
34
35
36
37
38
39
40

41 Method of Assigning participants to Treatment Groups and Randomisation

42
43 An independent statistician will organise the randomisation. The randomisation will be stratified by
44 sex at birth (male vs. female) and baseline diagnosis (affective vs. non-affective) as these
45 characteristics are associated with key outcomes in this study and any chance imbalances may bias
46 the analysis. Participants will be allocated to either the EBIRT (AMTx+) or EBIRT (DRS) treatment
47 groups using randomly permuted blocks of varying size within each stratum, to maintain
48 approximately equal group sizes over time. The randomisation sequences will be concealed within a
49 secured password protected website. On obtaining informed consent of a new participant, the
50 delegated research team member will access this website and enter the participant's details. The
51
52
53
54
55
56
57
58
59
60

1
2
3 delegated research team member will then inform the treating team the randomisation outcomes
4 who will then inform and discuss this with the participant.
5

6
7 A client identification (ID) number will be allocated to clients approached to ascertain their eligibility
8 to participate in the study. Each eligible participant will be allocated to a unique and sequential
9 randomization number.
10

11 12 Healthy Control Group

13
14 Because the age range of participants covers a time of significant neurodevelopment, 40 healthy
15 controls aged 15-25 years (inclusive), living in the EPPIC catchment, with no history of mental illness,
16 neurological condition or antipsychotic medication treatment will also be recruited. They will
17 undergo MRI scanning, be cognitively assessed and have physical health indicators measured (except
18 bloods) at the same four time points as the DRS+ and AMTx+ groups (baseline, 9-months, 15-months
19 and 24-months). This will provide objective control data to determine whether there are physical
20 health, brain volume and neural activation or cognition changes and if they are related to illness,
21 medication or typical development.
22
23
24
25
26

27 28 Outcome Measures

29 The primary outcome measure is the Social and Occupational Functioning Scale⁵⁹ (SOFAS) at 24 -
30 months. In addition to the primary outcome measure, a number of measures will assess physical
31 health and metabolic profiles, brain volumes/activity, cognitive functioning and remission and
32 relapse rates at 24-months.
33
34
35

36 37 Secondary Endpoint measures

38 39 Symptomatology

40 Remission and relapse of positive symptoms will be assessed using the expanded Brief Psychiatric
41 Rating Scale⁶⁰ (BPRS) in treatment groups only. Remission of negative symptoms will be assessed
42 using the Scale for Assessment of Negative Symptoms (SANS)⁶¹. The a priori clinically significant
43 degree of difference on duration of relapse is 7 days, in accordance with published duration
44 criteria⁵².
45
46
47

48 49 Neurocognitive assessments

50 A battery of neurocognitive tests including the Brief Assessment of Cognition in Schizophrenia⁶²
51 (BACS App) will be used to assess cognitive functioning in all groups, including healthy controls.
52 Further detail of the full neurocognitive battery can be found in the Schedule of Assessments (Table
53 1).
54
55
56
57
58
59
60

1
2
3
4
5 INSERT TABLE 1 ABOUT HERE
6
7
8
9

10 Physical health assessments

11 Blood pressure, weight, height and waist circumference will also be recorded in all groups including
12 healthy controls.
13

14 Haematological investigations

15 Physical health will be measured by clinical blood analysis evaluating fasting glucose, haemoglobin
16 A_{1c}, triglycerides and Total HL cholesterol in the treatment groups only.
17

18 Brain imaging

19 Brain volume will be quantified in both treatment groups and healthy controls by high-resolution
20 magnetic resonance imaging (MRI). In addition to structural MRI, functional resting state data will
21 also be collected.
22

23 Study Intervention

24 Intervention

25 After randomisation and allocation to one of the two conditions, all participants will commence the
26 intensive EBIRT phase in which they will attend up to twice weekly individual therapy and vocational
27 support sessions until Month 9.
28

29 Evidence-Based Intensive Recovery Treatment (EBIRT)

30 EBIRT combines two well-validated and manualised psychosocial interventions: Individual Placement
31 and Support (IPS) for vocational recovery and Cognitive Behaviour Therapy (CBT) for Relapse
32 Prevention. EBIRT will be delivered in two phases; a 9-month intensive phase which entails up to two
33 sessions of individual therapy (one CBT sessions and one IPS session) per week for 9-months. All
34 participants will receive 9 months of the EBIRT intensive phase. This will followed by a 6-9 month
35 (dependent on tenure remaining in service) - maintenance/monitoring phase in which individual
36 therapy sessions will be delivered every 4-6 weeks.
37

38 The first component of EBIRT is CBT. This will be provided by a therapist trained in CBT and is
39 comprised of six or more modules of therapy delivered over the 9-month intensive period. The six
40 phases of EBIRT intervention include: (1) initiation of vocational intervention (2) formulation and
41 agenda setting; including vocational goal setting; (3) engagement and assessment for recovery and
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 risk for relapse; (4) psychoeducation with a focus on relapse; (5) early warning signs and relapse
4 planning – will also involve family members with participant’s consent; and, treatment and progress
5 review (6). Additional optional modules may be drawn upon depending on case formulation and
6 clinical determination in collaboration with the participant include: substance abuse, stress
7 management, and co-morbid anxiety and depression at the participant or clinician discretion. The
8 second component of EBIRT is IPS. This will focus on (a) focussed upon competitive employment,
9 education or training as an outcome; and (b) focussed upon immediate job/education searching and
10 will be delivered by a Youth Specialist Vocational Consultant. In tandem with EBIRT, participants will
11 be randomly assigned following baseline assessment to either the DRS+ or AMTx treatment
12 conditions.
13
14
15
16
17
18

19 DRS will comprise a 9-month EBIRT phase (DRS+). The comparator group will receive AMTx and
20 EBIRT (AMTx+). The EBIRT intervention will be the same in both groups. The AMTx group treatment,
21 including medication prescription will be in accordance with published treatment guidelines. The
22 Reduce trial clinicians will collect data on frequency, content and duration of therapy sessions in
23 order to measure treatment compliance for the duration of the 15-18 month EBIRT treatment.
24
25
26
27
28

29 At Month 9, all participants will transition into the lower intensity monitoring phase of EBIRT in
30 which they will attend individual therapy sessions with their Reduce case manager every 4-6 weeks
31 for a minimum of 6 months. All participants will receive at least 15 months of total Reduce
32 treatment and a maximum of 18 months, depending on how long their psychotic symptoms take to
33 stabilise upon entry into EPPIC. This means that some participants will receive a total of 24 months
34 of EPPIC treatment whereby, some participants will receive 27 months total EPPIC treatment.
35 Participants are entitled to the full EPPIC treatment package throughout this time and can have the
36 frequency of appointments with EPPIC team increased should there be a clinical indication to do so.
37 Differences in EPPIC treatment will be recorded.
38
39
40
41
42
43

44 Dose Reduction Strategy (DRS+) group

45 Participants who are randomised to this arm of the trial will be offered a gradual dose reduction of
46 their antipsychotic medication at their next medical review after randomisation. Medication will be
47 tapered under close medical supervision over 3-months after allocation to the DRS group to
48 minimise the risk of relapse due to abrupt discontinuation. The rate of tapering will be a 25% dose
49 reduction (or as near to 25% as the medication allows) of the pre-reduction dose every month for 3
50 months, until the participant reduces a dose that is considered clinically safe, whereby some
51 participants will completely cease taking the antipsychotic medication. This will see some variation
52
53
54
55
56
57
58
59
60

1
2
3 in participants' reduction schedule. All data on the rate of dose reduction will be collected by the
4 Reduce clinicians to measure the variations in participant treatment.
5

6 Antipsychotic Maintenance Treatment (AMTx) group

7
8 Participants will be prescribed medication as clinically indicated, concordant with the Australian
9 Clinical Practice Guidelines for FEP^{54,55}. These guidelines recommend the use of the lowest effective
10 dose of atypical antipsychotics.
11
12

13
14 All trial participants will have access to all components of treatment at EPPIC, including psychiatric
15 care, case management, psychosocial program, acute inpatient care and outreach as clinically
16 indicated.^{58,61,62}
17
18

19 Safety Measures

20
21 Participants will be managed within the EPPIC clinic at OYH. Participants will be monitored by the
22 treating team. Clinical appointments can be held more frequently when clinically indicated. In
23 addition, the BPRS⁵⁸ and SOFAS⁵⁹ scales will administered weekly by the participant's EBIRT Clinician
24 to assess for participant symptomatic relapse, and to measure the acceptability and safety of the
25 prescribed dose. The SOFAS will measure functioning during the 9-month intensive phase. These
26 safety assessments will continue to occur every 4-6 weeks up until Month 24 and administered by
27 either the EBIRT Clinician or the Research Assistant.
28
29
30
31
32

33 Temporary Pause or Complete Discontinuation from DRS+

34
35 In the event of symptomatic relapse or worsening of symptoms, and the participant meeting the
36 criteria for relapse described in Table 2, the participant's dose reduction treatment may be
37 temporarily paused.
38
39
40

41 Table 2 presents the criteria used to define psychotic relapse and will result in a temporary pause
42 from the DRS+ treatment. These relapse criteria have been developed with the aim of reflecting
43 'real-world' relapse of FEP. Participants must satisfy either Criteria 1, 2 or 3 in combination with 4 to
44 meet relapse criteria.⁵⁸ There is also a 'fail-safe' option should stopping the DRS be clinically
45 indicated.
46
47
48

49 *TABLE 2 HERE*
50

51
52 Participants will be monitored by their treating team and study personnel and regularly assessed for
53 relapse, psychotic exacerbations and functioning.
54
55
56
57
58
59
60

1
2
3 In the event of a temporary pause in the dose reduction strategy the clinical team will decide
4 whether the participant should restart their antipsychotic medication or increase their dose. Any
5 changes made will be in consultation with the participant.
6
7

8 If antipsychotic medication is recommenced or if the dose is increased, it will be titrated up until an
9 effective dose is reached. Titration will occur at a pace appropriate to the individual's clinical
10 presentation and should allow adequate time for a response at each dosing interval. In this case,
11 psychiatry registrars will discuss appropriate dose with treating consultants and ensure any changes
12 are documented. If the participant fails to achieve satisfactory recovery defined by persistence of
13 severe psychotic symptoms whilst consistently meeting criteria described in Table 2 for 3 months
14 following the initial relapse, or if they become pregnant during the study they will be completely
15 discontinued from DRS+, whilst still remaining in EPPIC and receiving EBIRT. These participants will
16 also be invited to continue with the research assessments and included in intention-to-treat
17 analyses.
18
19
20
21
22
23

24 Table 3 outlines the study schema

25
26
27 *TABLE 3 HERE*
28

29 Participants discontinued from the AMTx+ group will continue to receive treatment in accordance
30 with the Australian Clinical Practice Guidelines. If they wish they may continue with EBIRT and the
31 research assessments. These participants will also be included in intention-to-treat analyses.
32
33
34

35 Withdrawal Criteria

36 A participant will be withdrawn from the study if they choose to no longer participate in the Reduce
37 study voluntarily, A participant will be considered 'withdrawn' from the study in cases where all
38 involvement in the trial is ceased and no further follow up is enacted
39
40
41

42 Blinding

43 The delegated study statistician will be blind to treatment allocation. Research assistants (RAs) will
44 also be blind to treatment allocation. The study RAs will be kept blind to treatment allocation using
45 the following processes: (a) regular reminders will be sent to clinical staff at EPPIC, regarding the
46 importance of the blind; (b) at the start of each research interview the RA will remind the
47 participants of the importance of the blind; (c) the RA will have restricted access to participants'
48 medical records. The unblinded Project Manager will have access to the participant's medical
49 records and will retrieve and provide study RA's with any information that is required (i.e. for
50 screening). Because the extent and rate of dose tapering in each individual case requires clinical
51
52
53
54
55
56
57
58
59
60

1
2
3 tailoring in response to preceding dose reductions, it is not feasible to utilise a placebo control, so
4 medication treatment will be open-label, with medications chosen by EPPIC psychiatrists.
5

6 7 Statistical methods and determination of sample size

8 Data analysis will be conducted at the completion of the study (24-months from last patient first
9 visit) and as such there will be no interim analyses conducted. The primary outcome is SOFAS score
10 at two-year follow-up. Calculations of effect size are based on detecting a two-year follow-up effect
11 size of $d=0.505$, based on our previous relapse prevention studies which found a group difference of
12 this magnitude on the SOFAS at two-year follow-up. Power is set at 0.85, $\alpha = .05$ (two-tailed). The
13 estimated sample size is 144 ($n=72$ per group). To accommodate an attrition rate of 20%, the target
14 sample size will be 180, or 90 participants per treatment group. Differences on social and vocational
15 functioning measures will be examined using mixed model repeated measures and intention-to-treat
16 analysis. Between-group differences on vocational status will be examined using logistic regression.
17 Patterns of missing data and missing data mechanisms will be investigated using two approaches;
18 firstly, Little's missing completely at random (MCAR) test will be used to assess the degree to which
19 the data are likely to meet the MCAR mechanism; secondly, prediction of missingness at each of the
20 assessment points will be undertaken using binary logistic regression, with a range of baseline
21 sociodemographic, clinical, and psychopathology variables used to predict the presence or absence
22 of a particular assessment. Likelihood techniques will be used to address missing data. The same
23 statistical models described above will be used to characterise the effects of treatment regimen on
24 grey and white matter volumes. Flexible factorial models will be used to estimate significant within-
25 and between-group activation effects at the whole brain level (using F-tests) to determine the
26 effects of treatment regimen on brain function. A cluster-based permutation approach will be used
27 to identify significant differences satisfying a Family Wise Error rate of .05. Age and sex assigned at
28 birth will be controlled for in all analyses.
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Data Safety Monitoring Board

44 A Data Safety Monitoring Board will be established in accordance with ICH-GCP Guidelines and the
45 NHMRC's 2018 guidelines on DSMBs.
46
47

48 Trial Status

49 The study commenced enrolling participants in July 2017. Enrolment is continuing at the time of
50 manuscript submission. The report of the study findings is expected in 2024.
51
52
53
54
55
56
57
58
59
60

Funding: The study is funded by an National Health Medical Research Council (NHMRC) Project grant (APP 1102394) from the Commonwealth of Australia. Killackey has been funded by an NHMRC CDF II Fellowship (APP1051891) and a Fellowship from the BB & A Miller Foundation. Alvarez-Jimenez was supported by a Career Development Fellowship (APP1082934) from the National Health and Medical Research Council. Nelson is funded by an NHMRC Senior Research Fellowship. Bendall is funded by a Fellowship from the McClusker Charitable Foundation. Allott is funded by a Ronald Philip Griffiths Fellowship, The University of Melbourne.

1. Addington J, Killackey E, Marulanda D. Early Psychosis Services. In: Yung AR, McGorry PD, eds. *Youth Mental Health: A Preventive Approach to Mental Disorders in Young People*. Melbourne: IP Communications; In Press.
2. Killackey E, Allott K. Utilising Individual Placement and Support to address unemployment and low education rates among individuals with psychotic disorders. *Australian and New Zealand Journal of Psychiatry*. 2013;47(6):521-523.
3. Waghorn G, Saha S, Harvey C, et al. 'Earning and learning' in those with psychotic disorders: The second Australian national survey of psychosis. *Australian and New Zealand Journal of Psychiatry*. 2012;46(8):774-785.
4. Horan WP, Subotnik, K. L., Snyder, K. S. & Nuechterlein, K. H. Do recent-onset schizophrenia patients experience a "social network crisis"? . *Psychiatry*. 2006;69:115-129.
5. Harvey C, Killackey E, Groves A, Herrman H. A place to live: housing needs for people with psychotic disorders identified in the second Australian survey of psychosis. *Australian and New Zealand Journal of Psychiatry*. 2012;46:840-850.
6. Morgan V, McGrath J, Jablensky A, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. *Psychological medicine*. 2013:1-14.
7. Morgan VA, Waterreus A, Jablensky A, et al. People Living with Psychotic Illness 2010. In: Department of Health and Ageing, ed. Canberra: Commonwealth of Australia; 2011.
8. Alvarez-Jimenez M, O'Donoghue B, Thompson A, et al. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era. *CNS Drugs*. 2016;30(5):357-368.
9. Ramsay CE, Broussard B, Goulding SM, et al. Life and treatment goals of individuals hospitalized for first-episode nonaffective psychosis. *Psychiatry research*. 2011;189(3):344-348.
10. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose

- 1
2
3 Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-
4 up of a 2-Year Randomized Clinical Trial. *JAMA Psychiatry*. 2013;70(9):913-920.
5 11. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided
6 discontinuation versus maintenance treatment in remitted first-episode psychosis:
7 relapse rates and functional outcome. *Journal of Clinical Psychiatry*. 2007;68(5):654-
8 661.
9
10 12. Correll CU, Rubio JM, Kane JK. What is the risk-benefit ratio of long-term
11 antipsychotic treatment in people with schizophrenia? *World Psychiatry*
12 2018;17:149-160.
13 13. Program EPGWGaENS. *Australian Clinical Guidelines for Early Psychosis, 2nd edition*
14 *update*. Melbourne: Orygen, The National Centre of Excellence in Youth Mental
15 Health, Melbourne.;2016.
16
17 14. Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D. Remission in
18 schizophrenia: proposed criteria and rationale for consensus. *American Journal of*
19 *Psychiatry*. 2005;162:441-449.
20 15. Knapp M, Patel A, Curran C, et al. Supported employment: cost-effectiveness across
21 six European sites. *World Psychiatry*. 2013;12(1):60-68.
22 16. Ascher-Svanum H, Zhu BJ, Faries DE, et al. The cost of relapse and the predictors of
23 relapse in the treatment of schizophrenia. *Bmc Psychiatry*. 2010;10.
24 17. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs,
25 clinical outcomes and quality of life. *British Journal of Psychiatry*. 2004;184:346-351.
26 18. Iyer SN, Mangala R, Anitha J, Thara R, Malla AK. An examination of patient-identified
27 goals for treatment in a first-episode programme in Chennai, India. *Early*
28 *Intervention in Psychiatry*. 2011;5(4):360-365.
29 19. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity,
30 and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. *Am J*
31 *Psychiatry*. 2013;170(6):609-615.
32 20. Sohler N, Adams BG, Barnes DM, Cohen GH, Prins SJ, Schwartz S. Weighing the
33 Evidence for Harm From Long-Term Treatment With Antipsychotic Medications: A
34 Systematic Review. [Article]. *American Journal of Orthopsychiatry*. 2016;86(5):477-
35 485.
36 21. Chen EYH, Hui CLM, Lam MML, et al. Maintenance treatment with quetiapine versus
37 discontinuation after one year of treatment in patients with remitted first episode
38 psychosis: randomised controlled trial. *British Medical Journal*. 2010;341.
39 22. Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in
40 schizophrenia. *Schizophrenia research*. 2013;148(1-3):117-121.
41 23. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. *Bmc*
42 *Psychiatry*. 2013;13.
43 24. Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I. A Review and
44 Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical
45 Neuroleptic Drugs Compared With Haloperidol and Placebo. *Journal of Clinical*
46 *Psychopharmacology*. 2011;31(6):698-704.
47 25. Grundy S, Brewer H, Jr. , Cleeman J, Smith S, Jr., Lenfant C. Definition of metabolic
48 syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart
49 Association conference on scientific issues related to definition. . *Circulation* 2004;
50 109(Jan 27):433-438.
51
52
53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
26. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. *Acta Psychiatrica Scandinavica*. 2002;106(4):286-290.
27. Whale R, Harris M, Kavanagh C, et al. Effectiveness of antipsychotics used in first episode psychosis: a naturalistic cohort study. *BJPsych Open*. 2016;2:323-329.
28. De Hert M, Correll C, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World psychiatry : official journal of the World Psychiatric Association*. 2011;10(1):52-77.
29. Subotnik KL, Nuechterlein KH, Ventura J, Marder S. Response to Gordon and Green Letter. *American Journal of Psychiatry*. 2011;168(9):987-988.
30. Olfson M, Gerhard T, Huang C, Crystal S, Stroup T. Premature mortality among adults with schizophrenia in the united states. *JAMA Psychiatry*. 2015:1-10.
31. Hage A, Weymann L, Bliznak L, Marker V, Mechler K, Dittmann RW. Non-adherence to Psychotropic Medication Among Adolescents - A Systematic Review of the Literature. *Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie*. 2018;46(1):69-78.
32. Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis. *Schizophr Bull*. 2011;37(3):619-630.
33. Bola JR, Mosher LR. At issue: Predicting drug-free treatment response in acute psychosis from the Soteria project. *Schizophrenia Bulletin*. 2002;28(4):559-575.
34. Lesh A, T, Tanase C, Geib B, R, et al. A Multimodal Analysis of Antipsychotic Effects on Brain Structure and Function in First-Episode Schizophrenia. *JAMA Psychiatry*. 2015.
35. Bowie CR, McLaughlin D, Carrion RE, Auther AM, Cornblatt BA. Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis. *Schizophrenia research*. 2012;137(1-3):110-117.
36. Lui S, Li T, Deng W, et al. Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. *Archives of General Psychiatry*. 2010;67(8):783-792.
37. Sarpal D, K, Robinson D, G, Lencz T, et al. Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia. *JAMA Psychiatry*. 2015;72(1):5-13.
38. Radua J, Borgwardt A, Crescini D, et al. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. *Neuroscience and Biobehavioral Reviews*. 2012;36:2325-2333.
39. Husa AP, Rannikko I, Moilanen J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study. *Schizophrenia research*. 2014;158(1-3):134-141.
40. Faber G, Smid HG, Van Gool AR, Wiersma D, Van Den Bosch RJ. The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. *Eur Psychiatry*. 2012;27(4):275-280.
41. Weickert TW, Mattay VS, Das S, et al. Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease. *Schizophrenia research*. 2013;149(1-3):162-166.

- 1
- 2
- 3 42. Knowles EEM, David AS, Reichenberg A. Processing Speed Deficits in Schizophrenia: Reexamining the Evidence. *American Journal of Psychiatry*. 2010;16(7):828-835.
- 4 43. Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. *Journal of Clinical Psychopharmacology*. 2001;21(5):479-483.
- 5 44. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of Cognitive Performances During a Placebo Period and an Atypical Antipsychotic Treatment Period in Schizophrenia: Critical Examination of Confounds. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2003;28:1497-1500.
- 6 45. Gleeson JF, Cotton SM, Alvarez-Jimenez M, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. *J Clin Psychiatry*. 2009;70(4):477-486.
- 7 46. McGorry PD, Alvarez-Jimenez M, Killackey E. Antipsychotic medication during the critical period following remission from first-episode psychosis. Less is more *JAMA Psychiatry*. 2013.
- 8 47. Alvarez-Jimenez M, Gleeson JF, Henry LP, et al. Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. *Psychological medicine*. 2012;42(3):595-606.
- 9 48. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. *American Journal of Psychiatry*. 2001;158(11):1835-1842.
- 10 49. McGorry P. Issues for DSM-V: Clinical staging: A heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. *American Journal of Psychiatry*. 2007;164(6):859-860.
- 11 50. Carpenter WT, Jr., Appelbaum PS, Levine RJ. The Declaration of Helsinki and clinical trials: A focus on placebo-controlled trials in schizophrenia. *American Journal of Psychiatry*. 2003;160(2):356-362.
- 12 51. Killackey E, Jackson HJ, McGorry PD. Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. *Br J Psychiatry*. 2008;193(2):114-120.
- 13 52. Gleeson JFM, Cotton SM, Alvarez-Jimenez M, et al. A Randomized Controlled Trial of Relapse Prevention Therapy for First-Episode Psychosis Patients: Outcome at 30-Month Follow-Up. *Schizophrenia Bulletin*. 2013;39(2):436-448.
- 14 53. Thompson A, Singh S, Birchwood M. Views of early psychosis clinicians on discontinuation of antipsychotic medication following symptom remission in first episode psychosis. *Early intervention in psychiatry*. 2016;10(4):355-361.
- 15 54. National Collaborating Centre for Mental Health. *Psychosis and Schizophrenia in adults: The NICE guideline on treatment and management. Updated edition 2014*. London: National Institute for Health and Care Excellence; 2014.
- 16 55. ORYGEN Youth Health. *The Australian Clinical Guidelines for Early Psychosis*. Melbourne: ORYGEN Youth Health Research Centre; 2010.
- 17 56. Association AP. *Diagnostic and statistical manual of mental disorders* 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
- 18 57. First MB WJ, Karg RS, Spitzer RL *Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)*. Arlington, VA: American Psychiatric Association; 2015.
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 58. Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green MF, Shaner A. *Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0). Scales, Anchor Points, and Administration Manual*. . West Los Angeles: UCLA Department of Psychiatry and Behavioral Sciences.; 1993.
- 4
5
6
7 59. Goldman HH, Skodol AE, Lave TR. Revising Axis V for DSM-IV: A review of measures of social functioning. *American Journal of Psychiatry*. 1992;149(9):1148-1156.
- 8
9 60. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychiatric Reports*. 1962;10:799-812.
- 10
11 61. Andreasen NC. *Scale for Assessment of Negative Symptoms (SANS)*.. Iowa City: University of Iowa; 1984.
- 12
13 62. Keefe RS, Harvey PD, Goldberg TE, et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). *Schizophrenia research*. 2008;102(1-3):108-115.
- 14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Dose reduction in FEP: Study Protocol

Table 1

Outline of Schedule of Assessments

	Visit 1 Baseline		Visit 2	Visit 3		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
Informed Consent ⁴	X					
Inclusion/Exclusion Criteria	X					
Demographics	X		X	X		X
Medical & Psychiatric History		X				
Pregnancy (urine) ⁵	X			X		X

¹ Core Baseline assessments may be conducted over a number of visits to allow for 'real-world' scenarios however, must be completed prior to randomisation.

² Non-Core Component Baseline assessments may be conducted over a number of visits to allow for 'real-world' scenarios and can be completed up to 3 weeks after randomisation.

³ Telephone contact every 6 weeks from Month 9-24 to check discontinuation/withdrawal criteria.

⁴ Informed consent can be obtained up to 21 days prior to baseline.

⁵ In addition to conducting urine pregnancy tests at each baseline and 24-month assessments, participants will also be asked to indicate whether they are pregnant or not during 9-month, 15-month assessments and telephone follow-ups.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
Concomitant Med. Review ⁶		X	X	X	X	X
Treatment Allocation						
Randomisation	X					
Diagnosis						
SCID5-RV (Modules A & B)	X			X		X
Intervention						
Participants in DRS+ ⁷						
EBIRT ⁸	←—————→			←-----→ Post intervention Follow up		

⁶ To maintain blinding of RAs, EBIRT clinicians will review medication adherence weekly (every second session) during the EBIRT intensive phase and every session during the EBIRT maintenance phase. EBIRT clinicians will also check concomitant medications every 6 weeks during the intervention phase (up to minimum of 15 months).

⁷ Reduce antipsychotic medication dose by 25% every month for 3 months as clinically indicated.

⁸ EBIRT intensive phase: Twice weekly individual therapy sessions to month 9, maintenance/monitoring phase 4-6 weeks individual therapy for a minimum of 6 months. A checklist recording details and items covered in of the EBIRT (CBT) Session will be completed every session by the Clinician and entered directly into the eCRF. The IPS Worker will also complete a checklist recording items covered in every session and enter this in to the eCRF. This data will be used to assess fidelity of EBIRT.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
Medication Compliance						
Clinician's compliance rating ⁵		X	X	X		
MARS ⁵		X	X	X		X
Medication side effects						
LUNTERS		X	X	X		X
Symptomatology						
BPRS ⁹	X		X	X	X	X
SANS		X	X	X		X
DASS-21		X	X	X	X	X
CDSS		X	X	X		X
IPASE		X	X	X		X
Functioning & Quality of Life						
SOFAS ⁸		X	X	X	X	X
Vocational functioning		X	X	X	X	X

⁹ In addition to assessment time-points and telephone follow-up, the BPRS and SOFAS will be measured weekly during the intensive phase and at therapy sessions during the maintenance phase for purposes of discontinuation criteria.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
WHOQoL-BREF		X	X	X		X
ULCAL5		X	X	X		X
MHCS		X	X	X		X
The Self-efficacy Scale		X	X	X		X
BPNS		X	X	X		X
Daily functioning and affect						
SEMA ¹⁰		X	X	X		X
Pre-morbidity and illness						
NOS		X				
Trauma						
CTQ		X				
Metabolic monitoring						
Clinical Bloods ¹¹		X	X	X		X

¹⁰ SEMA will be used to deliver electronic surveys (to be administered directly after the baseline and follow up assessments (visits 1-4) at 8 time points per day in the waking hours of each participant for a period of 7 days. Only participants who have smartphones will complete these surveys.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
Blood pressure, height, weight and waist circumference ¹²		X	X	X		X
Substance Use						
AUDIT		X	X	X		X
ASSIST		X	X	X		X
Neurocognitive						
WRAT-4		X				
BACS		X	X	X		X
ER-40		X	X	X		X
The Hinting Task		X	X	X		X

¹¹ Clinical bloods will involve testing for fasting glucose, haemoglobin A_{1c}, fasting triglycerides and fasting total HL cholesterol.. Clinical Bloods assessment to be completed within two weeks of randomisation and within two weeks of Visits 2 to 4.

¹² Blood pressure, height, weight and waist circumference will also be measured at approximately 12, 18, and 21 months in addition to study visits. These will be measured by study RAs.

Dose reduction in FEP: Study Protocol

	Visit 1 Baseline		Visit 2	Visit 3 End of Intervention		Visit 4 End of Study
	Core Baseline ¹ Day -21 to 1	Non- Core Baseline ² Day 1 to Day 21	9-month + 3 months	15-18 month + 3 months	Phone follow up ³ ± 7 days	24-month ± 28 days
Assessment						
PAL		X	X	X		X
Edinburgh Handedness Inventory		X				
NSSR		X	X	X		X
PDQ		X	X	X		X
AES		X	X	X		X
Structural and functional Imaging						
Shoulder and Hip width ¹³		X				
MRI ¹⁴		X	X	X		X

¹³ Eligibility assessment for MRI scan

¹⁴ MRI assessment to be completed within two weeks of randomisation and within two weeks of Visits 2 to 4.

Dose reduction in FEP: Study Protocol

Table 2 Temporary Pause from DRS+

1.	Increases from 3 (mild) or below to ratings of 6 or 7 (severe or very severe) on any one of the following 3 BPRS ⁴⁹ items: (i) unusual thought content, (ii) hallucinations, and (iii) conceptual disorganisation, with a duration criterion of 1 week;
2.	Significant psychotic exacerbations defined by an increase from 3 or below (for at least 1 month) on all the BPRS ⁴⁹ 3 scales followed by a score of 5 (moderate) on any of the 3-items plus a 2-point increase on one of the other scales (again with the addition of a duration criterion of 1 week) or a rating of 5 on any one of the 3 scales for at least 1 month.
3.	An increase in suicidality as defined by a score of 5 or more on the BPRS ⁴⁹ Suicidality subscale (i.e., many fantasies about suicide, specific suicide plan, non-lethal attempt) for a duration of at least 1 week.
AND	
4.	A significant decrease in overall functioning as defined by a 20-point drop in SOFAS score from the baseline score, maintained for one month.
OR	
5.	If the above criteria are not met but the participant is considered by their treating clinical team to have significantly deteriorated in relation to psychotic symptoms compared to baseline, and clinical response is deemed necessary, they may also be temporarily paused from the DRS+.

Table 3

Dose reduction in FEP: Study Protocol

Reduce Intervention Timeline

